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The goal of pathway analysis is to identify the pathways significantly impacted in a given
phenotype. Many current methods are based on algorithms that consider pathways as
simple gene lists, dramatically under-utilizing the knowledge that such pathways are meant
to capture. During the past few years, a plethora of methods claiming to incorporate
various aspects of the pathway topology have been proposed. These topology-based
methods, sometimes referred to as “third generation,” have the potential to better
model the phenomena described by pathways. Although there is now a large variety
of approaches used for this purpose, no review is currently available to offer guidance
for potential users and developers. This review covers 22 such topology-based pathway
analysis methods published in the last decade. We compare these methods based on:
type of pathways analyzed (e.g., signaling or metabolic), input (subset of genes, all genes,
fold changes, gene p-values, etc.), mathematical models, pathway scoring approaches,
output (one or more pathway scores, p-values, etc.) and implementation (web-based,
standalone, etc.). We identify and discuss challenges, arising both in methodology and
in pathway representation, including inconsistent terminology, different data formats, lack
of meaningful benchmarks, and the lack of tissue and condition specificity.
Keywords: pathway analysis, topology, signaling pathways, metabolic pathways, mathematical model, network
topology, statistical significance
1. INTRODUCTION
In molecular biology and genetics, there is a large gap between
current data analysis techniques and their ability to derive precise
and accurate functional information from the large and con-
stantly growing volume of high throughput molecular data. The
capability of obtaining a comprehensive lists of genes/proteins
that are different between two phenotypes is routine1 in research
today. And yet, the holy grail of high-throughput has not deliv-
ered so far. Even though high-throughput comparisons are
relatively easy to perform, understanding the phenomena that
determine the measured changes is as challenging as ever, if not
more so. Therefore, it is crucial to develop effective ways to ana-
lyze the vast amount of data that has been and will continue to be
collected.
A major contributor to the gap between our ability to collect
data and our ability to interpret it, is the fact that living organisms
are complex systems whose emerging phenotypes are the results
of thousands of complex interactions taking place on various
metabolic and signaling pathways. The ability to correctly infer
1Such experiments are currently offered by a number of academic cores
and private companies for a fixed and reasonable fee. Examples of such
cores include: Duke Proteomics Core Facility, Johns Hopkins Microarray
Core, CMMB Research Facility (Univ. of South Florida), MD Anderson Core
Facility, UCLA DNA Microarray Core Facility, Stanford Genomic Resources,
Dana-Farber Microarray Core, etc.
the perturbed pathways responsible for a phenotype from a list
of differentially expressed (DE) genes or proteins may be the key
to transforming the now abundant high-throughput expression
data into biological knowledge. In turn, this can help understand
mechanisms of disease, develop better drugs, personalize drug
regimens, etc. For our purposes, pathways are models describ-
ing the interactions of genes, proteins, or metabolites within cells,
tissues, or organisms, not simple lists of genes. This is why, in
this paper, we focus exclusively on pathway analysis methods that
aim to identify the pathways that are significantly impacted in
a condition under study, taking pathway topology into account.
This process uses two types of data: (i) previously accumulated
knowledge in the form of known pathways, represented as graphs
and (ii) experiment data, such as gene expression values or pro-
tein or metabolite abundance data obtained when comparing two
phenotypes.
In spite of the crucial importance of this problem and of the
recent increase in the number of methods and approaches for
pathway analysis, to our knowledge there is no current review
focused on topology-based methods. A reason for this may be
related to the challenges currently associated with this problem.
A first such challenge is the lack of standards for the evaluation
of the results of the analyses. This has lead to the proliferation of
many techniques that have never been compared with each other
in a consistent way. Another set of challenges is related to the
pathways themselves. Not only there is no universal agreement for
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the representation of information content in pathway databases,
but the very definition of a pathway is not completely agreed
upon Chowbina et al. (2009). Some authors use the term “path-
way” to refer to a simple list of genes (such as those associated
with a given Gene Ontology (GO) term), lacking any structure
and any information about the interactions between these genes.
Many others use graphs to capture relationships but the mean-
ing of edges and nodes varies dramatically from one source to
another. Figure 5 shows not fewer than five different types of
graphs, all referred to as “pathways.” Even pathways from the
same source, often use different representations. For instance,
genes/proteins are associated with nodes in KEGG signaling path-
ways while they are associated with edges in KEGG metabolic
pathways.
The subset of available techniques that consider the path-
ways as simple lists of genes, such as those associated with a
GO term (or another arbitrary descriptor) are worth of further
discussion. Here, we will refer to these as gene set analysis meth-
ods, rather than pathway analysis methods. A comprehensive list
of such techniques, as well as some comparisons between them
can be found in several well-developed surveys (Misman et al.,
2009; Chuang et al., 2010; Kelder et al., 2010; Emmert-Streib and
Glazko, 2011; Khatri et al., 2012).While useful for the purpose for
which they have been developed - to analyze sets of genes - these
methods do not take into consideration the topology of the path-
ways, and hence completely ignore the interactions described by
the pathways, the different types of genes, the position of the genes
on their respective pathways, etc. This is illustrated in Figure 1. In
some sense, the very reason for the existence of the pathways is to
describe the way various genes interact. Therefore, methods that
perform the analysis only on sets of genes, ignoring the topol-
ogy of the pathway, are not included in the scope of the present
review.
Recent pathway analysis algorithms have become more refined
than gene set analysis methods by incorporating topology
(Figure 2). A first attempt to incorporate topology informa-
tion in the analysis of pathways was through the use of graph
theory methods. This approach became popular in the last
decade (Chuang et al., 2010; Barabási et al., 2011). Aittokallio and
others survey graph-based analysis methods. They identify cate-
gories based on global structural properties, local structural con-
nectivity, or hierarchical functional organization, and describe
the features of gene regulatory networks, metabolic networks,
and protein-protein interaction (PPI) networks (Aittokallio and
Schwikowski, 2006). Some of these graph theory methods and
concepts are relevant to the pathway analysis methods able to
compare phenotypes, which are the focus of the current review.
However, as a broad category, the approaches based on graph
theory methods are not able to identify the pathways that are sig-
nificant in a given phenotype comparison and therefore, do not
fall within the scope of this review.
Varadan and others (Varadan et al., 2012) review the use of
biological knowledge bases for cancer diagnosis and prognosis.
They attempt to evaluate the performance of three topology-
based methods, SPIA, PARADIGM, and PathOlogist, on the same
input datasets to compare the biological relevance of their out-
puts. Unfortunately, since the 3 tools did not use the same
pathway database, the authors chose to re-implement SPIA and
adapt it to the pathway database used by the other two, so that the
result from all three would be comparable. The authors discuss
FIGURE 1 | Gene sets are not pathways. (A) shows a small part of
the MAPK signaling pathway from KEGG. This pathway shows the
location of various genes or gene products (inside the cell, outside of
it, or in the membrane), what gene interacts with what other gene(s),
the type of each interaction (activation, repression, phosphorylation,
etc.), the direction of the signal propagation, and potentially many other
things (e.g., complex formation, etc.). (B) presents the same part of the
same pathway as a gene set (no interactions). The gene set has lost
all the structure and the additional information captured by the original
pathway. This comparison shows how much important knowledge
existent in pathway database is ignored when pathways are treated as
simple gene sets.
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FIGURE 2 | Generalized overview of the data flow in pathway analysis methods. For each module, the various options available for different methods
surveyed, as well as the comparison criteria used in this paper are presented in the white boxes.
relative performance of the three methods, but could not draw
definitive conclusions regarding the superiority of one tool ver-
sus another. We also ran their version of SPIA and the original
SPIA implementation from Bioconductor, using exactly the same
input, and obtained different results. This indeed demonstrates
some of the inherent problems encountered when comparing
pathway analysis methods. First of all, it is difficult to success-
fully re-implement an algorithm to force it to work on other
data sources, especially when the re-implementation is done by
third parties. Furthermore, sometimes the mere ability to repro-
duce published results - which is at the base of modern scientific
research - is questionable in this area. For instance, in spite of hav-
ing access to the source code and having the full cooperation of
the authors, we could not even reproduce the results reported in
Vaske et al. (2010).
Four topology-based tools, along with several gene-based
methods, were recently reviewed by Khatri and others Khatri et al.
(2012). This recent survey groups functional analysis based on
GO together with pathway analysis methods. With this very loose
definition of a pathway and pathway analysis, the authors present
the limitations and challenges of various methods in general,
and categorize topology-based methods as “third-generation”
tools. However, even though it is very recent, this existing survey
only includes 4 out of the 22 topology-based analysis methods
reviewed here.
In a different direction, researchers tackle the problem of
understanding disease by looking at signaling networks from the
perspective of fault tolerance. Fault tolerance is a measure of the
vulnerability of signaling networks to the abnormal function of its
components. Abdi and Emamian survey this direction in a com-
prehensive study Abdi and Emamian (2010). Valuable results are
presented highlighting vulnerable molecules in different molec-
ular networks for biological phenomena such as mitosis or p53
signaling.
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Kinetic/stoichiometric models based on the molecular mecha-
nisms of interaction have been used for over 25 years in order to
simulate biochemical phenomena. Such models are in some sense
the ultimate tools because they can predict exact quantities for
any variable in the system. However, their use is limited by the
need to know the precise initial concentration for most reactants,
exact reaction constants for all reactions, as well as the appro-
priate time scale for the studied phenomenon. Furthermore,
the goals of such models are very different from the goals of
pathway analysis methods. The goal of such kinetic models is
to fully describe the biochemical phenomena involved and to
make quantitative predictions about some of the reaction prod-
ucts involved. In contrast, the goal of pathway analysis methods
is to identify the most significantly impacted pathways from a
large collection of heterogeneous pathways, based on incomplete
information. Furthermore, kinetic models work for biochemi-
cal pathways describing reactions of the same type (biochemical)
with known reaction constants (Steuer, 2007). The pathways
we are considering here include gene signaling pathways con-
taining different “signals” (inhibition, activation, phosphoryla-
tion, methylation, etc.) happening at many levels (transcription,
translation, post-translational, etc.) between heterogeneous com-
ponents (mRNA, DNA, protein, metabolites, etc.). Therefore,
the entire body of work concerned with modeling biochem-
ical pathways using mathematical models (e.g., differential or
difference equations) does not fall within the scope of this
review.
Finally, it is important to state that we do not intend to assess
the efficacy of each method, since there is not a universally recog-
nized correct output of such tools. Designing benchmark datasets
would help to determine the most effective mathematical model
but this is beyond the intended scope of the current review and
hence, it is not attempted here.
In this paper, we describe 22 topology-based pathway analy-
sis methods designed to analyze either signaling pathways (see
Figure 3), or metabolic pathways (Figure 4). There are sev-
eral commercial tools used for pathway analysis, which do not
incorporate the pathway topology when computing pathway
scores including Ingenuity Pathway Analysis (Ingenuity Systems,
www.ingenuity.com) and Genomatix (Genomatix Software,
www.genomatix.de). Since these tools only perform a gene set
analysis, failing to take advantage of the additional knowledge
incorporated in the pathways, they will not be considered
here. We found only two commercial tools that do incor-
porate topology in the pathway analysis. These are Pathway-
Guide (Advaita Corporation, http://www.advaitabio.com) and
MetaCore (Thomson Reuters, http://www.thomsonreuters.com).
We categorize and compare all surveyed methods based on dif-
ferent criteria including: the type of input required, the type of
output provided, the mathematical models used, and the imple-
mentation used. In section 2, we discuss the options for input
data in different tools, in particular, the challenges specific to
topology-based methods. Section 3 reviews the underlying math-
ematical models and scoring methods currently available to rate
pathway deregulation. Section 4 focuses on the types of out-
put provided. Finally, section 5 presents issues regarding the
implementation of the methods. To the best of our knowledge,
FIGURE 3 | Timeline showing when the surveyed pathway analysis
tools, working mainly with signaling pathways, became available (this
time may be different from publication time shown in Table 1). Some
of the methods use additional interaction information that may be from an
in-house or public gene/protein interaction knowledge base.
BAPA-IGGFD (Zhao et al., 2012) and TBScore (Ibrahim et al., 2012)
acronyms were assigned to the respective methods, in this manuscript, for
ease of reference. The commercial tools, Pathway-Guide and MetaCore are
not included in this figure.
FIGURE 4 | Timeline showing the availability of pathway analysis tools
that work mainly with metabolic pathways.
our review is the only comprehensive survey of topology-based
pathway analysis methods to date.
2. INPUT DATA
This review focuses on pathway analysis methods that try to
exploit some of the information contained in the pathway topol-
ogy in order to identify the pathways that are significantly
impacted in a condition under study. In order to address this
problem, any pathway analysis method will need: (i) a collec-
tion of pathways capturing our current knowledge about the
interactions of genes, proteins, metabolites, or compounds in
an organism (usually from a pathway database), and (ii) exper-
imental data in the form of measurements of gene expression,
protein abundance, metabolite concentration, or copy numbers.
The pathway data is accumulated, updated, and refined by amass-
ing knowledge from scientific literature describing individual
interactions or high throughput experiment results. The experi-
ment data is usually provided bymeasurements comparing two or
more phenotypes such as treated vs. untreated, disease vs. healthy,
or treated with drug A vs. drug B.
Analysis methods take various approaches to accommodate
the different formats commonly used for both types of data. In
this section, we compare all methods reviewed based on their
input types and formats, and discuss the particular difficulties
encountered when incorporating the pathway interactions into
topology-based analysis methods.
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2.1. EXPERIMENT DATA
Most methods analyze data from high-throughput experiments,
such as microarrays, next-generation sequencing, or proteomics.
Most analysis methods accept either a list of gene IDs or a list of
such gene IDs associated with measured changes. These changes
could be measured with different technologies and therefore can
serve as proxies for different biochemical entities. For instance,
one could use gene expression changes measured with microar-
rays, or protein levels measured with a proteomic approach, etc.
Transcription data is often used to approximate the proteome,
since high-throughput protein abundance data is not readily
available. Most methods expect a consistent input i.e., all val-
ues are expected to be of the same type. MetPA, which is a
metabolic pathway analysis method, is the only method that does
not accept gene expression. This method uses as input either a list
of “important” compounds, or a metabolite concentration table.
Different analysis methods use different input formats. Many
methods accept a list of all genes considered in the experiment
together with their expression values. Some analysis methods
select a subset of genes, considered to be differentially expressed
(DE), based on a predefined cut-off. The cut-off is typically
applied on fold-change, statistical significance, or both. A selec-
tion based on both criteria can be performed easily if the data is
displayed as a volcano plot, i.e., in a coordinate system that has
fold changes on the x axis and the negative log of the p-value
on the y axis. In such a plot, genes that have large absolute fold
changes as well as significant p-values will appear in the top part
of the plot, towards the sides. These methods use the list of DE
genes and their corresponding fold-change values as input. Other
methods use only the list of DE genes, without corresponding
expression values, because their scoring methods are based only
on the relative positions of the genes in the graph. Methods which
use cut-offs are sensitive to the chosen threshold value, because a
small change in the cut-off may drastically change the number
of selected genes (Nam and Kim, 2008). As a consequence, some
genes with moderate differential expression may be lost, even
though they might be important players in the impacted path-
ways (Ben-Shaul et al., 2005). Furthermore, the genes included in
the set of DE genes can vary dramatically if the selection meth-
ods are changed. Hence, the results of pathway analyses based on
DE genes may be vastly different depending on both the selection
method as well as the threshold value (Pan et al., 2005). On the
other hand, methods which do not use a threshold are more sen-
sitive to the noise coming from the (very many) genes that do not
change much between the two phenotypes, genes that are nor-
mally eliminated by the DE selection process. An approach used
to address this issue while still using all gene measurements uses
the individual p-values of each gene (Voichit¸a et al., 2012).
Among the surveyed methods, ScorePAGE, PathOlogist,
NetGSA, TopologyGSA, PWEA, TAPPA, ACST, BPA, BAPA-
IGGFD, and DEGraph use all genes together with their expression
values as input. However, for BPA and BAPA-IGGFD2, the fold
changes are only used to label each gene and not considered in
2BAPA-IGGFD (Zhao et al., 2012) and TBScore (Ibrahim et al., 2012)
acronyms were assigned to the respective methods, in this manuscript, for
ease of reference.
the analysis itself. In BPA, this label is whether the gene is DE or
not and in BAPA-IGGFD, the label states whether the gene is up-
regulated or down-regulated. Therefore, these two methods can
be categorized as using a cut-off on the input gene list. Methods
that use the DE gene list and their associated values include
Pathway-Guide, Pathway-Express, SPIA, and TBScore. However,
the impact analysis which is the approach used by Pathway-Guide,
Pathway-Express and SPIA has been recently extended to work
with the set of all genes as well (Voichit¸a et al., 2012), so these
can now be used either with or without DE genes. Moreover, this
functionality is now available as part of the Bioconductor pack-
age ROntoTools. 3 MetaCore, TopoGSA, and EnrichNet use only
the DE gene list without associated expression values. CePa is a
method that has two options. It can work with either a list of DE
genes, or the whole list of genes with their expression values and
phenotype labels. GANPA and THINK-Back Density Analysis
(DS) modify existing gene set analysis methods, such as GSEA, by
calculating topology-based weights for each gene before applying
the main gene set analysis method. In these methods, the gene set
analysis used in the second stage uses as input the list of all genes
with their expression values. However, the weighting process used
in the first stage requires DE genes with their values, for GANPA,
and the list of DE genes, for THINK-Back-DS.
2.2. PATHWAY DATA
Biological processes can be represented by different types of mod-
els. Usually pathways, such as signaling ormetabolic pathways, are
sets of genes and/or gene products that interact with each other
in a coordinated way to accomplish a given biological function
or process. A typical signaling pathway (in KEGG for instance)
uses nodes to represent genes or gene products and edges to
represent signals, such as activation or repression, that go from
one gene to another. A typical metabolic pathway uses nodes to
represent biochemical compounds and edges to represent reac-
tions that transform one or more compound(s) into one or more
other compounds. These reactions are usually carried out or con-
trolled by enzymes, which are in turn coded by genes. Hence, in
a metabolic pathway, genes or gene products are associated with
edges rather than nodes, as in a signaling pathway. The immediate
consequence of this difference is that many techniques cannot be
applied directly on all available pathways. There are other types
of biological networks that incorporate genome wide interactions
between genes or proteins such as protein-protein interaction
(PPI) networks. These networks are not restricted to specific bio-
logical functions. The main caveat related to PPI data is that most
such data are obtained from a bait-prey laboratory assay, rather
than from in vivo or in vitro studies. The fact that two proteins
stick to each other in an assay performed in an artificial envi-
ronment can be misleading since the two proteins may never be
present at the same time in the same tissue or the same part of the
cell.
The pathway data that is the input of the pathway analysis
methods, generally come from a single source such as a single
pathway database. In some analysis methods a second source
of interaction data is used, such as a gene/protein interaction
3http://bioconductor.org/packages/release/bioc/html/ROntoTools.html
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knowledge base or a genome scale network. Most of the meth-
ods use one data source. However, among the surveyed meth-
ods, MetaCore, GANPA, BAPA-IGGFD, and EnrichNet use two
sources of interaction data. MetaCore uses two types of propri-
etary knowledge: an interaction database, as well as canonical
pathways. The interaction information is protein-protein inter-
action data gathered from literature which is used to generate a
directed global network. There is no public information regard-
ing the details of how the MetaCore interaction network and
canonical pathways are created.
Another analysis method that uses two sources of data is
BAPA-IGGFD. The first source is a predefined pathway knowledge
base. BAPA-IGGFD is advertised as able to analyze any pathway
format; however the example in Zhao et al. (2012) is restricted
to pathways from the KEGG database. The second source is an
interaction knowledge base, called PrimeDB, which was created
by the authors of Zhao et al. (2012), by extracting directed gene-
gene interaction information from scientific publications and
past experiments. PrimeDB lists potential interactions between
each pair of genes and counts reported instances of activation and
inhibition separately.
EnrichNet and GANPA are other methods with two input
sources. They use genome-scale interaction networks in addi-
tion to predefined pathway datasets as input. For the genome-
scale interaction networks, EnrichNet uses PPI networks such
as STRING (Snel et al., 2000; Von Mering et al., 2003) and
GANPA builds a network, called gNET, based on different types
of gene/protein association databases such as PPIs, co-annotation
in GO Biological Process (BP), and co-expression in large-scale
gene expression microarray data.
Pathway analysis methods can use public or proprietary input
sources. MetaCore, BAPA-IGGFD, and GANPA use proprietary
interaction networks. All other surveyed methods use public
sources. Among them, TopoGSA infers PPI networks on the
fly, for human and some model organisms, from databases
such as MIPS (Mewes et al., 1999), DIP (Xenarios et al.,
2000), BIND (Bader et al., 2001), HPRD (Peri et al., 2004),
IntAct (Hermjakob et al., 2004), and BioGRID (Stark et al., 2006).
TopoGSA also accepts any kind of predefined pathways as input
which it scores and compares with the constructed network.
Publicly available curated pathway databases used by the sur-
veyed methods are KEGG (Ogata et al., 1999), NCI-PID (Schaefer
et al., 2009), BioCarta (BioCarta, 2000),WikiPathways (Pico et al.,
2008), PANTHER (Mi et al., 2005), and Reactome (Joshi-Tope
et al., 2005). These curated knowledge bases are more reliable
than protein interaction networks but do not include all known
genes and their interactions. As an example, KEGG included only
about 5000 human genes in signaling pathways, at the time of
writing this article.
Various research groups have tried different strategies to
address the challenge of modeling complex biomolecular phe-
nomena. These efforts have lead to variation among knowledge
bases, complicating the task of developing pathway analysis meth-
ods. There is currently no accepted standard for constructing
pathways, and as pathway paradigms evolve to better represent the
biology, pathway analysis methods evolve in parallel. Depending
on the database, there may be differences in: information sources,
experiment interpretation, models of molecular interactions, or
boundaries of the pathways. Therefore, it is possible that pathways
with the same designation and aiming to describe the same phe-
nomena may have different topologies in different databases. As
an example, one could compare the insulin signaling pathways of
KEGG and BioCarta. BioCarta includes fewer nodes and empha-
sizes the effect of insulin on transcription, while KEGG includes
transcription regulation as well as apoptosis and other biological
processes. However, BioCarta includes the C-JUN transcription
factor, which is missing from the KEGG representation.
Differences in graph models for molecular interactions are
particularly apparent when comparing the signaling pathways
in KEGG and NCI-PID. While KEGG represents the interaction
information using the directed edges themselves, NCI-PID intro-
duces “process nodes” to model interactions (see Figure 5). Most
pathway analysis methods are designed to use only one pathway
graph model, which limits the user’s possibilities. Developers are
faced with the challenge of modifying methods to accept novel
pathway databases or modifying the actual pathway graphs to
conform to the method.
Pathway databases not only differ in the way that interactions
are modeled, but their data are provided in different formats
as well (Chuang et al., 2010). Common formats are Pathway
Interaction Database eXtensible Markup Language (PID XML),
KEGG Markup Language (KGML), Biological Pathway Exchange
(BioPAX) Level 2 and Level 3, System Biology Markup Language
(SBML), and the Biological Connection Markup Language
(BCML) (Beltrame et al., 2011). The NCI provides a unified
assembly of BioCarta and Reactome, as well as their in-house
“NCI-Nature curated pathways,” in NCI-PID format (Schaefer
et al., 2009). In order to unify pathway databases, pathway infor-
mation should be provided in a common format. XML is a flexible
text format with increasing use for data exchange across different
systems. However, XML is very low-level and lacks standard con-
structs to accurately describe biological phenomena. PID XML
is both human- and machine-readable, and allows a platform-
independent means of exchanging PID data. The BioPAX project
is an effort to unify the format and exchange of pathway data,
and has incorporated independent sources such as NCI, BioCarta,
Reactome, and WikiPathways, UCSC, NIH, and others (BioPAX,
2002).
The implementation of analysis methods constrains the soft-
ware to accept a specific input pathway data format, while the
underlying graph models in the methods are independent of the
input format. Regardless of the pathway format, this must be
parsed into a computer readable graph data structure before being
processed. The implementation may incorporate a parser, or this
may be up to the user. For instance, SPIA accepts any signaling
pathway or network if it can be transformed into an adjacency
matrix representing a directed graph where all nodes are compo-
nents and all edges are interactions. NetGSA is similarly flexible
with regard to signaling and metabolic pathways. SPIA provides
KEGG signaling pathways as a set of pre-parsed adjacency matri-
ces. The methods described in this paper may be restricted to
only one pathway database, or may accept several. The cor-
responding databases for the surveyed methods are shown in
Table 1.
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FIGURE 5 | Comparison of representative graph models for molecular
interactions as used by different pathway databases. In a KEGG
signaling pathway (A) nodes represent genes/gene products and edges
represent regulatory signals such as activation, inhibition, phosphorylation,
etc. (see http://www.genome.jp/kegg/document/help_pathway.html for
details). In the chemical network representation of a KEGG metabolic
pathway (B) the nodes represent biochemical compounds and edges
represent chemical reactions. These chemical reactions are performed by
enzymes which are proteins encoded by genes. Hence, in contrast with
the signaling pathways in which genes are associated with nodes, in a
metabolic pathways genes are associated with edges. This is the main
reason most methods developed for signaling pathways cannot be applied
directly to metabolic pathways. In an NCI-PID signaling pathway (C) nodes
fall in two categories: component nodes representing biomolecular
components, or process nodes representing biochemical reactions or
biological processes. Edges connect two biomolecular components
through a biochemical reaction or a biological process. Process nodes can
have 3 states: positive regulation, negative regulation, or “involved in.”
(see http://pid.nci.nih.gov/userguide/network_maps.shtml for details). In a
protein-protein interaction network (D) nodes represent proteins and the
interactions among them represent physical binding. These interactions
can be inferred from two-hybrid assays and they may be either undirected
(top), or directed from the bait protein to the prey protein (bottom). In the
Biological Pathway Exchange (BioPAX) (E) nodes are physical entities and
edges are conversions. BioPAX entities can represent complexes, DNA,
proteins, RNA, small molecules, DNA regions or RNA regions. Conversions
can represent biochemical reactions complex assembly or degradation,
transport or transport with biochemical reaction. This model is very generic
and increasingly flexible. It provides a standard for pathway information to
be available in machine readable format, therefore easy to use for pathway
analysis and to exchange between pathway databases (see http://www.
biopax.org/release/biopax-level3-documentation.pdf for details).
3. MATHEMATICAL MODELS
For topology-based pathway analysis methods, the mathematical
model describes how the graph and the experiment data are pro-
cessed to compute a score for each pathway. The score quantifies
the significance of changes in a (sub)pathway between the two
phenotypes. This score may be a statistical significance or other
non-statistical method-specific metric. The diversity of current
topological based pathway analysis methods reflects the variety of
mathematical models available for graphs. The output is typically
a list of ranked (sub)pathways.
3.1. GRAPH MODELS
Two major graph models are used to represent biological net-
works and pathways. The first model, hereon referred to as
“single-type,” allows only one type of node, the biological compo-
nent (i.e., a gene or protein), with edges representing molecular
interactions occurring between the nodes (e.g., Figure 5A). In
contrast, the second graph model, hereon referred to as “multi-
type,” allows multiple type of nodes, such as components and
interactions (e.g., Figure 5C). Multi-type graph models are more
complex than single-type, but they capture more pathway char-
acteristics. For example, single-type models are limited when
trying to describe “all” and “any” relations between multiple
components that are involved in the same interaction. Bipartite
graphs, which contain two types of nodes and allow connection
only between nodes of different types, are a particular case of
multi-type graph models.
In most databases, pathways use the single-type graph model
and the signaling and metabolic pathways from databases such
KEGG and BioCarta are good examples. In signaling pathways,
nodes are genes and edges describe various molecular interac-
tions, which include activation/transcription/positive regulation,
repression/blockage/negative regulation, (de)phosphorylation,
binding/association. Metabolic pathways can be represented as
either chemical networks or protein networks. In the chem-
ical network representation, nodes are metabolites and edges
are enzymes and/or substrates that catalyze the chemical reac-
tions. In the protein network, the representation is reversed;
nodes are enzymes and edges are metabolites. Among the sur-
veyed methods which work with metabolic pathways only MetPA
uses biochemical networks from KEGG. ScorePAGE and TAPPA
use protein networks. Nevertheless, the most popular represen-
tation of metabolic pathways in public databases is the chemi-
cal network. In KEGG and BioCarta, the majority of edges in
both metabolic and signaling pathways are directed, but binding
between compounds is represented by undirected edges.
Protein-protein interaction (PPI) networks, constructed from
interaction databases, use a single-type graph model. The nodes
represent proteins and the edges depict their association/binding.
Sometimes the edges are undirected, while some other times, the
edges are directed to describe which protein was used as the bait
and which one acted as the prey.
Reactome and NCI-PID are databases that use a bipartite
graphmodel to represent pathways. Genes, metabolites, ormolec-
ular complexes are represented as component nodes, while inter-
action nodes define the chemical reactions or molecular processes
that occur between the input and output component nodes. The
edges, which connect a component node to an interaction node,
specify the component’s type of contribution to the reaction.
These can be positive or negative regulation, among others.
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Table 1 | Comparison of topology-based pathway analysis methods based on different criteria related to the input.
Method name Experiment input Interaction network database name Year References
ScorePAGE All genes expression KEGG metabolic 2004 Rahnenführer et al., 2004
MetaCore* DE genes list Literature-based genome-scale interaction network;
proprietary canonical pathway, genome-scale
network
2004 N/A
Pathway-Express DE genes with values,
All genes expression**
KEGG signaling 2005 Khatri et al., 2005,
Draˇghici et al., 2007,
Khatri et al., 2007,
Voichit¸a et al., 2012
TAPPA All genes expression KEGG metabolic 2007 Gao and Wang, 2007
PathOlogist All genes expression KEGG 2007 Efroni et al., 2007
Pathway-Guide* DE genes with fold change
(FC) values, DE genes list,
All genes with values, DE
genes with FCs and p-values
KEGG signaling, REACTOME, NCI, BioCarta 2009 N/A
SPIA DE genes with values KEGG signaling 2009 Tarca et al., 2009
NetGSA All genes expression KEGG signaling 2009 Shojaie and Michailidis, 2009,
Shojaie and Michailidis, 2010
PWEA All genes expression YeastNet 2010 Hung et al., 2010
TopoGSA DE genes list Genome-scale PPI network, KEGG 2010 Glaab et al., 2010
PARADIGM All genes expression, copy
number, proteins level
Constructed PPI networks from MIPS, DIP, BIND,
HPRD, IntAct, and BioGRID
2010 Vaske et al., 2010
TopologyGSA All genes expression NCI-PID 2010 Massa et al., 2010
DEGraph All genes expression KEGG 2010 Jacob et al., 2010
MetPA DE metabolites with values KEGG metabolic 2010 Xia and Wishart, 2010
BPA All genes expression -
with cut-off
NCI-PID 2011 Isci et al., 2011
GANPA DE genes with values,
All genes expression
Genome-scale PPI network, KEGG, REACTOME,
NCI-PID, HumanCyc
2011 Fang et al., 2011
BAPA-IGGFD All genes expression -
with cut-off
Literature-based gene-gene interaction database,
KEGG, WikiPathways, REACTOME, MSigDB,
GO BP, PANTHER;
constructed gene association network from PPIs;
co-annotation in GO Biological Process (BP); and
co-expression in microarray data
2012 Zhao et al., 2012
CePa DE genes list / All genes
expression
NCI-PID 2012 Gu et al., 2012
THINK-Back-DS DE genes with values,
All genes expression
KEGG, PANTHER, BioCarta, REACTOME,
GenMAPP
2012 Farfán et al., 2012
TBScore DE genes with values KEGG signaling 2012 Ibrahim et al., 2012
ACST All genes expression KEGG signaling 2012 Mieczkowski et al., 2012
(Continued)
Frontiers in Physiology | Computational Physiology and Medicine October 2013 | Volume 4 | Article 278 | 8
Mitrea et al. Topology-based pathway analysis methods
Table 1 | Continued
Method name Experiment input Interaction network database name Year References
EnrichNet DE genes list Genome-scale PPI network, KEGG, BioCarta,
WikiPathways, REACTOME, NCI-PID, InterPro,
GO with STRING 9.0
2012 Glaab et al., 2012
*commercial methods; **released in 2013 as part of ROntoTools.
(http://www.bioconductor.org/packages/release/bioc/html/ROntoTools.html)
N/A, No publication available. Experiment input describes the type of experiment data input required by the method. The meaning of each term is as follows: “DE
genes with values/DE metabolites with values” represents the list of differentially expressed (DE) genes or metabolites with their fold-change value or t-statistics.
Sometimes this list is accompanied by the list of total genes monitored in the experiment; “DE genes list” represents a list of selected genes, usually DE genes
(this is just a list of IDs, without associated fold-changes). “All genes expression” represents the list of all genes in all samples together with their expression
values. Some methods require all genes, but then perform the analysis using a flag for the DE genes - these are marked as “with cut-off.” Some methods use
one type of input in a gene weighting stage while using another type of input to assess the pathway significance. Interaction network type and database name
is the input knowledge source for the analysis method and the databases proposed by the software. Some of the methods can use any pathway, but provide
parsed data for the pathway databases listed here. “Pathway” refers to any kind of signaling or metabolic pathway or gene regulatory network. “Genome scale
interaction network” refers to interaction networks constructed from protein interactions or co-annotation from GO databases, literature, or co-expression inferred
from existing microarray experiments. “Constructed network” means that the analysis method uses pathways created by its authors rather than pathways from a
reference database. Year denotes the year of the first published paper describing the method. References denotes the first published paper describing the method.
The majority of analysis methods surveyed here use a single-
type graph model. Some apply the analysis on a directed or
un-directed single-type network built using the input pathway,
while others transform the pathways into graphs with specific
characteristics. An example of the later is TopologyGSA, which
transforms the directed input pathway into an undirected decom-
posable graph, that has the advantage of being easily broken down
into separate modules (Lauritzen, 1996). In this method, decom-
posable graphs are used to find “important” submodules - those
which drive the changes across the whole pathway. For each path-
way, TopologyGSA creates an undirected moral graph4 from the
underlying directed acyclic graph (DAG) by connecting the par-
ents of each child and removing the edge direction. The moral
graph is then used to test the hypothesis that the underlying net-
work is changed significantly between the two phenotypes. If the
the research hypothesis is rejected, a decomposable/triangulated
graph is generated from the moral graph by adding new edges.
This graph is broken into the maximal possible submodules and
the hypothesis is re-tested on each of them.
BPA is another method that implements pathway graph pre-
processing. This method uses Bayesian networks to represent
biological pathways. In Bayesian networks, random variables are
assigned to each node of a DAG network and the edges represent
the conditional dependencies between nodes. Before assigning the
random variables, the pathway graph is checked for cycles. If the
graph is not a DAG, Spirtes’ method (Spirtes, 1995) is used to
remove the cycles while the (in)dependency rules in the initial
pathway graph are preserved.
Another example is BAPA-IGGFD, which is a method that
simplifies pathway graphs by removing any edge representing
4The moral graph of a DAG is the undirected graph created by adding an
(undirected) edge between all parents of the same node (sometimes called
marrying), and then replacing all directed edges by undirected edges. The
name stems from the fact that, in a moral graph, two nodes that have a
common child are required to be married by sharing an edge.
interactions other than activation and inhibition. In addition,
the pathways are pruned keeping only elements from three cat-
egories: signal receptors (including ligands) are at the beginning,
transcription factors are usually at the end, and their direct regu-
lators are in the middle. This pre-processing is motivated by noise
reduction in the final scoring of genes that have a less important
functional role in the pathway or belong to multiple pathways
where they play different roles. (Zhao et al., 2012) includes only
an intuitive high-level description of this process is presented,
without a detailed algorithm.
CePa uses a different method to modify the input pathways
before the analysis. The NCI knowledge base is used as a source
of NCI-Nature, BioCarta, Reactome, and KEGG pathways, which
are provided in PID or short NCI-PID format. The pathway data
is organized in the form of multi-type graphs, which are used to
generate directed single-type graphs, where each node can rep-
resent one or multiple genes. A node in the generated graph
is considered to be DE if any of its gene components is DE.
Unfortunately, the details of how the original pathways are parsed
to generate the new networks are not provided by the authors of
CePa.
PathOlogist and PARADIGM are the two surveyed meth-
ods that use multi-type graph models. PathOlogist uses a
bipartite graph model with component and interaction nodes.
PARADIGM, conceptually motivated by the central dogma of
molecular biology, takes a pathway graph as input and converts
it into a more detailed graph, where each component node is
replaced by several more specific nodes: biological entity nodes,
interaction nodes, and nodes containing observed experiment
data. The observed experiment nodes could in principle contain
gene expression and copy number information. Biological entity
nodes are DNA, mRNA, protein, and active protein. The inter-
action nodes are transcription, translation, or protein activation,
among others. Biological entity and interaction node values are
derived from these data and specify the probability of the node
being active. These are the hidden states of the model.
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3.2. SCORING METHODS
The goal of the scoring method is to compute a score for each
pathway based on the graph model, resulting in a ranked list of
pathways or sub-pathways. There are a variety of approaches to
quantify the changes in a pathway. Some of the analysis meth-
ods use a hierarchically aggregated scoring algorithm, where on
the first level, a score is calculated and assigned to each node
or pair of nodes (component and/or interaction). On the sec-
ond level, these scores are aggregated to compute the score of the
pathway. On the last level, the statistical significance of the path-
way score is assessed using univariate hypothesis testing. Another
approach, used by BPA, BAPA-IGGFD, NetGSA, TopologyGSA,
and DEGraph, assigns a random variable to each node and a mul-
tivariate probability distribution is calculated for each pathway.
The output score can be calculated in two ways. One way is to use
multivariate hypothesis testing to assess the statistical significance
of changes in the pathway distribution between the two pheno-
types. The other way is to estimate the distribution parameters
based on the Bayesian network model and use this distribution
to compute a probabilistic score to measure the changes. In this
section, we provide details regarding the scoring algorithms of the
surveyed methods. See Figure 6 for scoring algorithms categories.
3.2.1. Hierarchically Aggregated Scoring Algorithms
These analysis approaches are detailed in Figure 7. In this fig-
ure, the analysis is divided into three levels: node-level scoring,
pathway-level scoring and significance assessment. All methods
compute node level scores. One or both remaining levels may be
skipped by certain approaches. PARADIGM is the only one that
provides as direct output the node scores, rather than the path-
way scores. These scores can be input into a gene set or pathway
analysis algorithm, or a simple averaging function can be used to
score the pathways and rank them, as in Vaske et al. (2010). The
rest of the methods go on to the second level where the scores
of the pathways are calculated. Some methods stop at the second
level, outputting the whole list of ranked pathways without evalu-
ating their statistical significance, which is done by the remaining
methods on the next level.
Node Level Scoring. Here we categorize and describe the sur-
veyed methods based on their node level scoring model. Most
of the surveyed analysis methods incorporate pathway topol-
ogy information in the node scores. There are methods such
as TAPPA and ACST that incorporate this information in the
pathway scores. In TAPPA, the score of each node is the square
root of the normalized log gene expressions (node value). ACST
calculates the node level score using a sign statistic. The sign
reflects the direction of the gene expression change between
the phenotypes under study. This statistic can be a represented
by a t-value or the log fold change of the gene expression.
The statistic is standardized using a local mean and standard
deviation.
The rest of the analysis algorithms use a variety of approaches
to incorporate topology in the node level scores. We categorize
them into methods that use graph measures (centrality), similar-
ity measures, and probabilistic graphical models. TBScore is an
exception that can not fall into either of these groups. TBScore
weights the pathway DE genes based on their log fold change and
FIGURE 6 | Comparison of the mathematical models of the surveyed
pathway analysis methods. “Aggregate scoring” and “Weighted gene set”
panels show methods that perform node-level scoring followed by
pathway-level scoring performed either as an aggregation of the node scores
or as a weighted gene set analysis, using the node scores as weights. The
methods are divided according to their node-level scoring methods: graph
measure techniques, similarity measurement techniques, probabilistic
models, or using normalized node values based on node value and/or
pathway structure. The “Multivariate scoring” methods use multivariate
scoring models without node-level scoring. They use node values to directly
compute a pathway score using Bayesian networks or applying multivariate
hypothesis tests.
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FIGURE 7 | Diagram of pathway analysis scoring approach for hierarchically aggregated scoring algorithms. The box with the dashed border indicates
that the user can choose these options, but are not offered by the method implementation.
the number of distinct DE genes directly downstream of them,
using a depth-first search algorithm.
MetaCore, Pathway-Guide, Pathway-Express, SPIA, TopoGSA,
CePa, EnrichNet, MetPA, THINK-BACK-DS, and GANPA use
centrality measures or a variation of these measures to score
nodes in a given pathway. Centralitymeasures describe the impor-
tance of a node relative to all other nodes in a network. There
are several centrality measures that can be applied to networks
of genes and their interactions and these are degree centrality,
closeness, betweenness, and eigenvector centrality. Degree cen-
trality accounts for the number of directed edges that enter and
leave each node. Closeness sums the shortest distance from each
node to all other nodes in the network. Node betweenness adds a
layer of complexity to closeness; it measures the importance of a
node according to the number of shortest paths that pass through
it. Eigenvector centrality uses the network adjacency matrix of a
graph to determine a dominant eigenvector; each element of this
vector is a score for the corresponding node. Thus, each score
is influenced by the scores of neighboring nodes. In the case of
directed graphs, a node that has many downstream genes has
more influence and receives a higher score.
In MetaCore, a measure similar to node betweenness is used
to score genes. There is no peer-reviewed paper publicly available
describing the details of the MetaCore pathway analysis method.
We used the study by Dezso˝ et al. (2009) to uncover some of
these details. In the method by Dezso˝ et al., the DE gene list is
overlapped with a global genome scale network containing all the
interactions in theMetaCore knowledge base. A network, which is
called condition specific shortest-path network (CSSPN), is built
based on this overlap. In addition to DE genes, all genes which
are on shortest paths that connect them in the global network are
included in the CSSPN. For each pair of genes (gi, gj), where gi is
in the CSSPN and gj is in the set of DE genes, two parameters Nij
and Kij are computed. Nij is the number of times gi is part of the
shortest-paths in the global network between gj and every other
gene in the CSSPN. Kij is the number of times gi is part of the
shortest-paths in the global network between gj and every other
gene in the set of DE genes. It is assumed that the probability to
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observe these numbers just by chance, given the two sets of genes,
the global network which is of sizeN and the DE genes which is of
sizeK, follows a hypergeometric distribution. Based on this distri-
bution, K p-values are computed for each gene in the CSSPN and
the minimum of these p-values is selected as the gene score. Using
a predefined threshold on the false discovery rate (FDR) correc-
tion of the node scores, a subset of the CSSPN genes is selected.
Further processing, in the pathway level scoring, is applied to this
list of selected genes.
Pathway-Guide, Pathway-Express, and SPIA use a perturba-
tion factor, which takes into consideration the magnitude of all
gene expression changes, the type of each gene, the direction
and type of all gene interactions, as well as the efficiency with
which the perturbation of each gene propagates to the down-
stream genes. The impact analysis models the flow of the signals
in the pathways. In essence, the impact factor falls into the eigen-
vector centrality category of node scoring approaches. Although
all three methods use the same impact analysis approach, there
are slight differences between them. Pathway-Guide scores the
pathways based on the impact factor as briefly described above
In SPIA, the amount of differential expression is subtracted from
the perturbation score of each node to focus on the amount of
perturbation accumulated at any given node in order to separate
the influence of experiment data and topology. Pathway-Guide
is also able to exploit the p-values associated with each gene,
as well as identify coherent perturbation cascades that repre-
sent putative mechanisms that explain all measured changes. All
three methods combine the perturbation evidence with a classi-
cal enrichment (e.g., hypergeometric), or functional class scoring
(e.g., GSEA) to calculate a global p-value. This corresponds to the
joint probability of a pathway having the measured amount of
perturbation, as well as the observed number of DE genes just by
chance. TBscore has an interestingly similar approach in captur-
ing the pathway perturbation, with the difference that DE genes
with more connected downstream DE genes are considered more
significant.
TopoGSA extracts a network from databases of protein inter-
actions given a list of genes/proteins of interest. All four types
of centrality measures and a fifth measure, called a “clustering
coefficient” (Watts and Strogatz, 1998) are used to score the
nodes in this network. Then, each predefined pathway from a
selected dataset is also scored using the same five measures, inde-
pendently of the extracted network. Comparing the summarized
node scores for each pathway with node scores from the extracted
network allows the pathways to be ranked.
In CePa, node weights are computed using five centrality-
based measures, and there is an extra case where all the node
weights are assumed to be equal. The five measures are: in-degree,
out-degree, betweenness, in-reach (length of longest shortest path
that starts from the node), and out-reach (length of longest short-
est path that ends at the node). CePa offers two options to assess
the significance of pathways. One is based on the hypergeometric
analysis using only node weights. The second is based on enrich-
ment analysis and in addition to node weights, node scores are
needed. Node scores are computed using a t-statistic. Pathway
graphs in CePa can contain nodes representing one or multiple
genes. In the case of single-gene nodes, the score is calculated
based on the expression value of the corresponding gene. In the
case of multi-gene nodes, the node score is the largest principal
component of the expression values of the genes in the node.
EnrichNet uses a score similar to centrality closeness measures.
This method calculates two distance vectors. The first vector
contains distances between a list of input genes and a prede-
fined pathway/gene set. The second vector contains the distance
between the same input gene list and a background global set con-
taining all pathways. A node score is computed as the distance
between the node and all DE genes using a random walk with
restart algorithm (Yin et al., 2010) through a genome scale molec-
ular interaction network. The interaction network is represented
by its weighted adjacency matrix, where weights are interaction
strengths provided by the input knowledge base.
MetPA allows the user to select either the node betweenness
or the out-node degree centrality measure for the node score.
GANPA (Fang et al., 2011) uses the node degree measure as a
weight or score for the gene. THINK-Back-DS uses a measure
similar to closeness called density score to emphasize the DE genes
which are in tight clusters.
ScorePAGE and PWEA use similarity measures in their node
level scoring. Similarity measures estimate the coexpression,
behavioral similarity, or co-regulation of pairs of components.
Their values can be correlation coefficients, covariances, or dot
products of the gene expression profile across time or sample.
In these methods, the pathways with clusters of highly correlated
genes are considered more significant. At the node level, a score
is assigned to each pair of nodes in the network which is the
ratio of one similarity measure over the shortest path distance
between these nodes. Thus, the topology information is captured
in the node score by incorporating the shortest path distance of
the pair. In ScorePAGE, the correlation coefficient, covariance, or
dot product is calculated for all gene pairs across their samples.
PWEA uses the correlation coefficient to score node pairs. In this
method, a score, called “Topological Influence Factor,” or TIF, is
assigned to each gene by exponentially averaging the score of all
pairs that include the gene. As a consequence, a node involved in
tight clusters of highly correlated genes has a higher score.
PARADIGM and PathOlogist incorporate the topology in the
node level scoring using a probabilistic graphical model. In this
model, nodes are random variables, and edges define the con-
ditional dependency of the nodes they link. PARADIGM takes
observed experiment data and calculates scores for all component
nodes, in both observed and hidden states, from the detailed net-
work created by the method based on the input pathway. For each
node score, a positive or negative value denotes how likely it is
for the node to be active or inactive, respectively. The scores are
calculated tomaximize the occurrence probability of the observed
values. A p-value is associated with each score of each sample such
that each node can be tagged as significantly active, significantly
inactive, or not-significant. For each network, amatrix of p-values
is output, in which columns are samples, and rows are component
nodes.
PathOlogist is also based on a probabilistic graphical model.
This method estimates the parameters of one or two distributions
related to the up and/or down regulation of each gene using its
expression values across all samples. These distributions are used
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to assign a probability score to each gene in each sample, denot-
ing how likely it is for the gene to be highly expressed. Themethod
assigns two different scores to interaction nodes: (i) the “activity
score,” which is the probability that the parents of an interaction
node (which are component nodes) are highly expressed, and (ii)
the “consistency score,” which is the probability that the interac-
tion node is active and its children are expressed or inactive with
unexpressed children.
Pathway Scoring Level. In the following, we describe how node
scores are used to compute pathway scores. Many of the sur-
veyed methods aggregate node level statistics to pathway level
statistics using linear functions such as averaging or summa-
tion. The methods that use linear aggregation in this level of the
analysis are: TopoGSA, MetaCore, MetPA, ScorePAGE, TBScore,
ACST, PathOlogist, Pathway-Guide, Pathway-Express, and SPIA.
The rest of the methods either use a nonlinear function to aggre-
gate the node scores to pathway scores, like TAPPA, PARADIGM,
and EnrichNet, or apply a gene set analysis method on the node
scores, like GANPA, CePa, THINK-Back-DS, and PWEA.
In MetaCore, important genes are selected in the gene level
scoring based on the list of DE genes and the network topology.
At the pathway level, this method assumes that the number of
selected genes that fall on a pathway is the pathway score and
follows the hypergeometric distribution.
In TAPPA, the pathway score for each sample is a weighted sum
of the product of all node pair scores in the pathway. The weight
coefficient is 0 when there is no edge between a pair. For any con-
nected node pair the weight is a sign function, which represents
joint up- or down-regulation of the pair.
In ACST, pathway scores are calculated based on the position
of node (gene) clusters for which the interaction types match the
up- or down-regulation of genes. This uses the same concept of
coherent signals used by Pathway-Guide. An edge (interaction)
between 2 components in a pathway is called consistent if either
(i) the pair has an inhibition interaction, and the directions of
differential expression of the components is opposite, or (ii) the
pair has an activation interaction, and the direction of differential
expression of the components is the same. All other interaction
types are ignored. Maximal consistent graphs are defined as max-
imal sub-networks of the pathway in which all interactions are
consistent. The score of each maximal consistent sub-graph is the
summation of all node scores. The pathway score is the sum of
the scores of all its maximal consistent sub-graphs. Node scores
are t-statistics normalized by the distance from the sub-graph to
the leaves of the pathway graph. The authors argue that the con-
sistent sub-graphs close to the leaves of the pathway have a greater
impact on the score of pathway rather than the clusters from the
beginning of the pathway. This is somewhat different from the
approach that Pathway-Guide, Pathway-Express, and SPIA follow.
Although in these methods there is no explicit weighting based
on the up- or down-stream position of a gene in a pathway, just
because the perturbation of one gene is propagated following the
signals described by the pathway, the perturbation of a gene some-
what near the entry point in a pathway will have more impact
than the same amount of perturbation for a gene somewhere
downstream on the pathway. Only time and additional testing
will tell which of the two approaches manages to capture better
the biological phenomena.
In EnrichNet, pathway scores measure the difference of the
node score distribution for a pathway and a background net-
work/gene set which consists of all pathways. At the node level,
the distance of all DE genes to the pathway is measured and
summarized as a distance distribution. The method assumes that
the most relevant pathway is the one with the greatest difference
between the pathway node score distribution and the background
score distribution. The difference between the two distributions
is measured by the weighted averaging of the difference between
the two discretized and normalized distributions. The averaging
method down-weights the higher distance nodes and emphasizes
the lower distance ones.
Methods such as Pathway-Guide, Pathway-Express, SPIA, and
MetPA use two types of analysis to score the pathways. For each
pathway, these methods calculate both a topology based score and
a p-value from a gene set enrichment analysis measure, such as
Fisher’s exact test, hypergeometric, or GlobalAncova. Pathway-
Guide, Pathway-Express, and SPIA use the joint probability of
observing the pathway perturbation, as well as the gene enrich-
ment on a given pathway (Draˇghici et al., 2007). This model
effectively combines the topology-based pathway score with the
one based on enrichment to provide a single global pathway
score. MetPA (Xia and Wishart, 2010) also looks at both enrich-
ment and topology, but does not assess the significance of the
topology-based pathway scores and does not combine the two
scores, and thus lacks a unique significance ranking. The most
impacted pathways in MetPA are those with higher scores in both
measures. It is not clear how to treat a trade-off between the two
types of significance.
The pathway scoring techniques described so far in this sec-
tion incorporate in-house analysis methods. A different direction
is to design scoring techniques that incorporate existing gene
set analysis methods, such as GSEA (Subramanian et al., 2005),
GSA (Efron and Tibshirani, 2007), or LRPath (Sartor et al., 2009).
Pathway-level scores can be calculated using node scores which
represent the topology characteristic of the pathway as weight
adjustments to a gene set analysis method. PWEA, GANPA,
THINK-Back-DS, and CePa use this approach and we refer to
them as weighted gene set analysis methods. GSEA calculates the
correlation coefficient of phenotype with gene expression (CC),
GSA and LRPath use the t-test statistic in the computation of
the node score. To compute the pathway score, PWEA adjusts
the CC exponent of 0 or 1 in GSEA to CCTIF+1, where TIF is
the node weight described above. The node weights calculated by
GANPA, THINK-Back-DS, and CePa are used to adjust CC or the
t-statistic by multiplication, node weight × CC or node weight ×
t − statistic. In CePa there is another option to use a hypergeo-
metric analysis to calculate pathway scores. In this method, the
node weights of DE nodes are summed up to the pathway level.
Some methods such as Pathway-Guide, Pathway-Express,
SPIA, and ROntoTools offer the flexibility to integrate in the
analysis any type of enrichment technique. Thus, the p-values
provided by techniques such as GSEA, GSA, or PADOG (Tarca
et al., 2012) can be used instead of the p-values provided by
simpler models such as hypergeometric.
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Pathway Significance Assessment. Pathway scores are intended to
provide information regarding the amount of change incurred by
the pathway between two phenotypes. However, the amount of
change is not meaningful by itself since any amount of change
can take place just by chance (i.e., the amount of change is only
the effect size). An assessment of the significance of the measured
changes is thus required, and should be done by analysis methods
in the pathway significance assessment level.
Methods such as TopoGSA, MetPA, and EnrichNet, will out-
put scores without any significance assessment, leaving it up to the
user to interpret the results. This is problematic because the user
does not have any instrument to help distinguish between changes
due to noise or random causes, and meaningful changes, unlikely
to occur just by chance and therefore, possibly related to the phe-
notype. The rest of the analysis methods perform a hypothesis
testing for each pathway. The null hypothesis is that the value of
the observed statistic is due to random noise or chance alone.
The research hypothesis is that the observed values are substan-
tial enough that they are potentially related to the phenotype. A
p-value for calculated score is then computed and a user-defined
threshold on the p-value is used to decide whether the the null
hypothesis can be rejected or not for each pathway. Finally, a
correction for multiple comparisons should be performed.
Typically, pathway analysis methods compute one score per
pathway. However, methods such as PathOlogist and TAPPA
compute the pathway score considering each sample separately.
Therefore, for each pathway there is a population of scores that
can be analyzed. This population combined with different sam-
ple features can provide various feature-specific analyses. There
are two cases to be considered based on the qualitative or quan-
titative nature of the sample feature values. In the first case the
sample feature is qualitative with binary values. For example,
when samples are tagged corresponding to the two phenotypes,
the significance assessment is done by testing whether the score
distributions are the same in the two groups using two-sample
rank-sum tests, such as the Mann–Whitney U-test. If the number
of samples is high enough, the score distributions can be assumed
to be normal. The null hypothesis here is that the two nor-
mal distributions have equal means and variances, the research
hypothesis is that they are different. In the second case the sample
feature is quantitative with continuous values. Two ways to iden-
tify significant pathways are implemented in this case. One way is
to partition pathway scores into a known number of clusters, for
example two, using k-means clustering. Cumulative distributions
are calculated for each of the two classes. A logrank test (Mantel,
1966), which is a non-parametric statistical test, can be performed
to evaluate whether the behavior of the variable is same in the two
groups. Significant pathways are those that can be used to divide
samples into groups with different characteristics. Another way to
identify significant pathways in the case of continuous sample fea-
ture values is to find pathways whose scores are linearly correlated
with the values of the feature. The null hypothesis in this case is
that the correlation is zero, and a t-test is used.
For methods that calculate one score per pathway, the distri-
bution of this score under the null hypothesis can be constructed
and compared to the observed. However, there are often too few
samples to calculate this distribution, so it is assumed that the
distribution is known. For example, in MetaCore and many other
techniques, when the pathway score is the number of DE nodes
that fall on the pathway, the distribution is assumed to be hyper-
geometric. However, the hypergeometric distribution assumes
that the variables (genes in this case) are independent, which is
incorrect, as witnessed by the fact that the pathway graph struc-
ture itself is designed to reflect the specific ways in which the genes
influence each other. Another approach to identify the distribu-
tion is to use statistical techniques such as the bootstrap method
(Efron, 1979). Bootstrapping can be done either at the sample
level, by permuting the sample labels, or at gene set level, by
permuting the the values assigned to the genes in the set.
To create the score distribution under the null hypothesis,
Pathway-Guide, Pathway-Express, and SPIA methods use boot-
strapping at the gene set level. For these methods, samples are
drawn from the distribution of all DE genes and assigned to a gene
set which is different from the DE gene set but with equal num-
ber. The pathway score is computed assuming the new gene set
as a decoy DE gene set. This procedure is repeated for a number
of iterations. The scores resulting from these iterations estimate
the distribution, which is then used to compute a p-value, and a
pathway score is obtained by combining the gene set enrichment
evidence with the topology-based p-value and applying Fisher’s
exact test. The final score is the FDR-adjusted p-value.
TBScore, the hypergeometric extension of CePa, and ACST
calculate p-values using bootstrapping at the sample level by
permuting the labels of the samples of the two phenotypes.
In TBScore and CePa, an iterative procedure is then used to
estimate the pathway score distribution under the null hypoth-
esis. Correction for multiple comparison, again FDR, is used
to compute the final pathway p-values. In ACST, after p-values
are computed, a statistical technique called “resampling-based
point estimator” is used to estimate the FDRs associated with the
predefined threshold.
Weighted gene set methods surveyed here, PWEA, GANPA,
the enrichment analysis extension implemented by CePa, and
THINK-Back-DS, focus on providing a biologically meaningful
topology-based adjustment to existing gene set analysis methods.
Therefore the statistical assessment of pathway significance is pro-
vided by the already developed methods among which the most
popular is GSEA (see Figure 7).
3.2.2. Multivariate scoring algorithms
Multivariate scoring analysis methods mostly use multivariate
probability distributions to score pathways and can be grouped
in two categories. Methods in the first category use multivari-
ate hypothesis testing, while methods in the second category are
based on Bayesian network (see Figure 8).
NetGSA, TopologyGSA, and DEGraph are methods based on
multivariate hypothesis testing. These analysis methods assume
the vectors of gene expression values in each (sub)pathway are
random vectors with multivariate normal distributions. The net-
work topology information is stored in the covariance matrix of
the corresponding distribution. For a network, if the two distri-
butions of the gene expression vectors corresponding to the two
phenotypes are significantly different, the network is assumed to
be significantly impacted when comparing the two phenotypes.
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FIGURE 8 | Diagram of pathway analysis scoring approaches for multivariate scoring algorithms.
The significance assessment is done by a multivariate hypothesis
test. The definition of the null hypothesis for the statistical tests
and the techniques to calculate the parameters of the distributions
are the main differences between these three analysis methods.
In NetGSA, it is assumed that the expression level of the genes
(nodes in the network) obtained from experiments are correlated
because of the interactions between them. In other words, the
edges (interactions) of a graph (pathway) imply correlations. In
order to compute the distribution parameters, themethod defines
a set of latent variables, which are the uncorrelated gene expres-
sions. The input correlated gene expression vector can be written
in the form of the product of the vector of latent variables and
the influence matrix. This matrix consists of the weights assigned
to each edge measuring the strength of the interaction between
two genes. The influence matrix and other parameters for the
two phenotypes are computed based on linear mixed model the-
ory (McLean et al., 1991). The proposed hypothesis test, in this
method, is to check whether a linear combination of the mean of
the latent variables, called contrast vector, for the two cases are
equal. The proposed contrast vector is computed based on the
influencematrix and it is proved that the result includes the effects
of all nodes inside a chosen network and excludes any outside
effects, such as the correlation.
In TopologyGSA, the directed graph is converted into a moral
undirected graph, detailed in Section 3.1. The covariancematrices
for each of the two phenotypes are estimated using the Iterative
Proportional Scaling (IPS) algorithm (Lauritzen, 1996) on the
sample covariance for all pairs of genes. The two matrices are
defined such that their inverses have zero elements correspond-
ing to the missing edges. A set of two hypothesis tests are applied
to compute the statistical significance of the impact on a given
graph. The first test checks whether the concentration matrices,
i.e., the inverses of the covariance matrices, in the two cases are
equal. If this hypothesis is rejected, the graph is broken into the
maximal possible submodules, and the hypothesis is retested on
each. Based on the equality of concentration matrices, different
statistical techniques are used in the second hypothesis test. The
second test checks the significance of the influence of the graphs
based on the equality of the means of the distributions.
DEGraph finds significant (sub)pathways by using a modi-
fied multivariate Hotelling T2-test hypothesis. The modification
incorporates the topology of the network. The difference, referred
to as shift, between the mean vectors of gene expression distri-
butions corresponding to the two phenotypes is smoothed. A
shift vector is defined to be smooth if the shift values of every
two connected nodes are similar. The process of smoothing is
done by removing the high frequency shift values according to
the topology of the network. This is achieved by filtering the
shift by preserving only the first few components of the graph-
Fourier basis of the shift vector. The graph-Fourier in DEGraph
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is applied by spectral analysis of the graph Laplacian (Chung,
1997), which resembles the Fourier decomposition of a func-
tion. The smoothed shift vector is used in the Hotelling T2-test
to assess the statistical significance of a network. DEGraph also
provides an algorithm that allows the exhaustive testing of all the
sub-networks of the original network using a branch and bound
algorithm.
BPA and BAPA-IGGFD are two methods based on Bayesian
networks. In a Bayesian network, which is a special case of prob-
abilistic graphical models, a random variable is assigned to each
node of a directed acyclic (DAG) graph. The edges in the graph
represent the conditional probabilities between nodes, so that the
children are independent from each other and the rest of the
graph when conditioned on the parents. In BPA, the value of the
Bayesian random variable assigned to each node captures the state
of a gene (DE or not). In contrast, in BAPA-IGGFD each random
variable assigned to an edge is the probability that up or down
regulation of the genes at both ends of an interaction are con-
cordant with the type of interaction which can be activation or
inhibition. In both BPA and BAPA-IGGFD, each random variable
is assumed to follow a binomial distribution whose probability of
success follows a beta distribution. However, these two methods
use different approaches in representing the multivariate distri-
bution of the corresponding random vector. BPA assumes that the
random vector has a multinomial distribution, which is the gen-
eralization of the binomial distribution. In this case, the vector of
the success probability follows the Dirichlet distribution, which
is the multivariate extension of the beta distribution. Conversely,
BAPA-IGGFD assumes the random variables are independent,
therefore the multivariate distributions are calculated by multi-
plying the distributions of the random variables in the vector.
It is worth mentioning that the assumption of independence in
BAPA-IGGFD is contradicted by evidence, specifically in the case
of edges that share nodes.
In BPA a discretized fold change profile is calculated for each
gene. This represents the list of fold changes between every
ordered pair of gene expression samples. The pair elements
come from each of the groups corresponding to the two phe-
notypes. These fold changes are discretized such that genes with
values higher than 2 or lower than 0.5 are considered differen-
tially expressed and the others are considered to have negligible
changes. This profile is used as the observed data for the Bayesian
network model. In BPA, given a set of parameters (success prob-
abilities), the likelihood of observing a specific profile on the
Bayesian network is assumed to have a multinomial distribu-
tion. Using the Bayes rule, the probability of observing the given
profile without any assumption on the parameters is calculated.
The parameters of the distributions are learned from the input
data (Neapolitan, 2004). The network topology is incorporated in
the distribution parameters and computation method by assum-
ing that knowing the values of the parents’ random variables,
the children random variables are independent of the rest of the
graph. A hypothesis testing is performed using the null hypoth-
esis that the probability of seeing the observed data is the result
of chance. Specifically, a set of observed data is generated in the
bootstrapping analysis and its probability is compared with the
the original observed data. The null distribution is approximated
through randomization via bootstrapping. This randomization
targets the structure of the Baeysian network (i.e., the relation
between its nodes), which is more relevant than a simple boot-
strapping in this case. Sampling with replacement is used when
generating random data. An upper-tailed test is performed, with
the p-value estimated by the percentage of random scores higher
than the observed one. The process of generating the randomized
samples is done by bootstrapping. A new fold change profile is
generated by sampling with replacement from the original fold
change profile.
In BAPA-IGGFD, based on the value of the fold change,
discretized values of 0 or 1, corresponding to up- or down-
regulation, are assigned to each node of the Bayesian network.
For each predefined pathway, a vector of probabilities is com-
puted as follows: (1) θ¯i for any parent-less gene gi is the
probability of gi being up-regulated, (2) θi|j for any gene gi
which has an activator parent gj is the probability that both
genes are coherent in being up-regulated or down-regulated,
and (3) φi|j for any gene gi which has an inhibitor parent
gj is the probability that the state of up or down regula-
tion of the genes are opposite. The vector can be summarized
as θ = ({θ¯i|∀gi is parent-less}, {θi|j|∀gi has an activator parent},
{φi|j|∀gj has an inhibitor parent}) which is called the parameter
vector of the pathway. Each of these parameters are assumed
to be independent from each other and follow the beta distri-
bution both prior observing the microarray data and after its
observation. Themultivariate joint distributions of the parameter
vector prior and posterior of the data observation are compared
using symmetric Kullback-Leibler (SKL) divergence (Kullback
and Leibler, 1951). The pathways for which the prior and pos-
terior distributions are dis-similar are assumed to be impacted
more significantly between the two phenotypes. Because of the
independence assumption, the distribution of the parameter vec-
tor is calculated by multiplying the beta distribution of each of
the parameters. The variables of the distributions are calculated
using PrimeDB database, or in other words, using the number
of journal citations for an interaction type. More details regard-
ing PrimeDB are available in section 2.2. We refer to beta(α, β) as
the beta distribution with parameters α and β. For the prior dis-
tribution, it is assumed that θ¯i ∼ beta(1, 1), θi|j ∼ beta(ai|j, bi|j),
and φi|j ∼ beta(bi|j, ai|j), where ai|j and bi|j are the number of
journals citing the activation or inhibition between gi and gj,
respectively. For the posterior distribution, it is assumed that θ¯i ∼
beta(n¯i, n − n¯i), θi|j ∼ beta(ai|j + ni|j, bi|j + n − ni|j), and φi|j ∼
beta(bi|j + ni|j, ai|j + n − ni|j), where n is the total number of
microarray experiments, ni is the number of experiments in
which gi is up-regulated, and ni|j is the number of experiments
in which the pairs gi and gj are concordant in up or down reg-
ulation. An extension to this method is proposed in which the
variables of beta distributions are not calculated by the input as
fixed numbers but are assumed to follow exponential distribu-
tions. In this case, the parameters of the exponential distributions
are estimated from PrimeDB and the input data. It is claimed
that this additional probability layer will lead to more robust
results. For genes that have more than one parent the major-
ity rule is used to calculate the distribution. The output of this
method is the list of pathways scored by the SKL divergence.
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The lower the score is the more impacted the pathway is
assumed to be.
4. OUTPUT
Although the goal of the pathway analysis should be a ranked
list of pathways as a unified output, not all tools reviewed here
provide this. Somemethods, such as MetPA provide a list of path-
ways with 2 p-values for each pathway, leaving the user to face
the task of deciding which p-value to trust or how to deal with
trade-offs between the two values. Among the methods that rank
predefined pathways from public knowledge bases, some meth-
ods, such as TopologyGSA, DEgraph, NetGSA, and ACST, find
“important” sub-pathways and rank the mixed list of pathways
and sub-pathways. In PARADIGM, for each detailed network
created by the method based on the input pathway, a matrix
of p-values is provided as the output. In this matrix, columns
are samples and rows are component nodes of the network.
Each element of this matrix indicates how likely it is for the
node to be in any of the three states comparing the two phe-
notypes: (1) significantly active, (2) significantly inactive, or (3)
have an insignificant change. These scores can be used as sub-
stitutes for log fold changes and, as proposed in Vaske et al.
(2010), can be input into a non-topology-based gene set analy-
sis algorithm to rank the pathways. Other options to use these
scores are either to apply a simple averaging or counting func-
tion on the scores of the significant genes to score the pathway,
or they can be used to cluster the genes into groups with similar
behavior. These clusters of genes can be used to further ana-
lyze different features assigned to samples to find group-specific
features.
Pathway-Guide offers capability to identify so called “coher-
ent chains of perturbation propagation,” which are to be
interpreted as putative mechanisms that are compatible with
(and therefore could explain) all measured changes throughout
the entire biological system investigated. Even though unique
among all other tools and potentially very useful, this capa-
bility is completely independent from the pathway ranking
provided based on the perturbation and enrichment types of
evidence. Therefore, it is possible for pathways that are sig-
nificant not to contain such coherent signaling cascades, and
conversely, pathways that may contain such cascades may not be
significant.
In many input data sets, the samples are labeled based on dif-
ferent parameters. The parameters can have qualitative discrete
values such as, tumor and normal tissue, or quantitative continu-
ous values such as, survival time of the cell or drug concentration
used to treat the tissue. For analysis methods that provide a
pathway score for each sample, such as TAPPA and PathOlogist,
the pathway activities can be interpreted based on the sample
labels. NetGSA (Shojaie and Michailidis, 2010) offers more label-
ing options in addition to phenotype-based binary labels. The
method provides simultaneous tests of multiple hypotheses based
on these labels or temporal pathway score correlation to assess
the significance of pathways. The rest of the pathway analysis
methods compare the pathways using a single qualitative binary
label corresponding to the two phenotypes. Methods such as
TopoGSA, MetPA, and the hypergeometric extension of CePa
calculate one score for each pair of input samples comparing the
two phenotypes, while others provide one score for the whole
input data set.
Some of the methods provide a graphical display of their
results. This is primarily done for the analysis methods which
have the ability to provide more than one score for each pathway.
For example, analysis methods like TopoGSA have an additional
option to compare the properties of the input dataset to pre-
defined datasets corresponding to known functional processes
from public databases in a comparative plot. As a result, a
summary of network topological properties is displayed for all
gene/protein sets in 2D and 3D plots. This functionality allows
the user to visually identify an input similar to the original
one, based on the plots or based on a tabular ranking using a
numerical score to quantify the similarity across all topological
properties. Similarly, analysis methods such as Pathway-Guide,
Pathway-Express, SPIA, and MetPA which provide two scores
(topology based and gene set enrichment) can use a 2D plot
to illustrate the distribution of both scores for the analyzed
pathways.
From the perspective of the output, the result pathway analysis
methods is typically a ranked list of pathways. However, there are
tools that only provide nodes scores and further use this scores as
input for an existing gene set analysis method. Visual display of
the results is a welcomed addition provided by Pathway-Express,
Pathway-Guide, SPIA, TopoGSA and MetPA.
5. IMPLEMENTATION
The mathematical model presented in Section 3 for each analy-
sis approach is independent of its implementation as a software
package. Although the main strength of an approach lies in its
algorithm, its implementation can have an important role in
reaching the full potential of that approach, as well as in gain-
ing acceptance among the users. Practicality, user-friendliness,
output format, and type of interface are all to be considered.
Depending on the desired availability and intended audience, a
software package may be implemented as standalone or web-
based.
Web-based tools run the analyses on a remote server providing
computational power and a graphical interface. On the user side,
experiment datasets are uploaded, and on the server side, the tool
performs the analysis. The results are displayed by the browser
in the format provided by the tool. The output of most pathway
analysis methods is a ranked list of pathways or sub-pathways.
MetPA, THINK-Back-DS and, EnrichNet are among the methods
that have web-based implementations. The major advantage of
web-based tools is that they are user-friendly and do not require
a separate local installation procedure.
Standalone tools need to be installed on local machines which
often requires administrative skills. Advantages include instant
availability that does not require internet access. Most standalone
tools depend on full or partial copies of public pathway databases,
stored locally, and need to be updated periodically. Methods like
Pathway-Guide, ScorePAGE, SPIA, TAPPA, PathOlogist, NetGSA,
TopologyGSA, PWEA, ACST, BPA, and GANPA are in this cate-
gory. Moreover, there are some methods available both as web-
based and standalone, including Pathway-Express, MetaCore,
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TopoGSA, CePa, and PARADIGM.5 Another major advantage of
standalone tools are the security and privacy of the experiment
data.
The programming language and style used for implementation
plays an important role in the acceptance of a method. Software
tools that are neatly implemented, packaged, and available online
are more appealing compared to those that do not have ready-
to-use implementations. Many of the methods surveyed here
are implemented in the R programming language and are avail-
able as software packages either from bioconductor.org, cran.r-
project.org, or the author’s website. Their popularity among
biologists and bioinformaticians is due to the fact that many
bioinformatics dedicated packages are available in R. Pathway-
Express (as part of ROntoTools), SPIA, TopoGSA, TopologyGSA,
GANPA, DEGraph, NetGSA, ACST, CePa, and ScorePAGE are
among thosemethods. Pathway-Guide, Pathway-Express, TAPPA,
and THINK-Back-DS have an implementation in Java, which
provides a GUI with self explanatory functionality for users with
less software development experience. This allows users to cus-
tomize the graphical display of the results, using functionalities
such as zoom or rotation. CePa has a web-based implementation
in Perl in addition to its R standalone package. TheMATLAB pro-
gramming language is used for implementation of methods like
PathOlogist, BPA, and NetGSA in order to calculate more com-
plex equations. Other programming languages like C and C++
are also used to implement pathway analysis methods such as
PARADIGM and PWEA, which theoretically provide better speed
and allow for efficient coding. A summary of the mathematical
models and implementation details for the surveyed methods is
presented in Table 2.
From the accessibility perspective, web-based tools have the
advantage of being available from any location as long as there
is an internet connection and a browser available. Also, the
update is almost seamless to the client. This makes the user’s task
easy and enables collaboration. Users all over the world can use
the same method without the burden of installing it or keep-
ing it up-to-date. The downside, once the internet connection
fails, the tool is unavailable. However, there are methods that
provide both web-based and standalone implementations and
these are: MetaCore, Pathway-Express, PARADIGM, CePa and
THINK-Back-DS.
6. CONCLUSIONS
Pathway analysis is a core strategy of many basic research, clinical
research, and translational medicine programs. Emerging appli-
cations range from targeting and modeling disease networks to
screening chemical or ligand libraries, to identification/validation
of drug target interactions for improved efficacy and safety (Arrell
and Terzic, 2010). The integration of molecular interaction infor-
mation into pathway analysis represents a major advance in the
development of mathematical techniques aimed at the evalua-
tion of systems perturbations in biological entities. Out of the
22 topological pathway analysis methods presented here, 15 were
5The web-based implementation is only available as part of TCGA while the
standalone is available only as C++ source code that needs to be compiled and
deployed locally.
published in the last 3 years, evidence that there is great interest
and desire for progress in this area.
The important milestones in pathway analysis reflected by this
survey are: the first pathway analysis method for metabolic net-
works (Rahnenführer et al., 2004), the first method for signaling
pathway and the first method able to take into consideration
the pathway topology (Khatri et al., 2005; Draˇghici et al., 2007),
the first application of topology-based multivariate hypothesis
tests (Shojaie and Michailidis, 2009), and the first analysis able
using multi-type graphs from heterogeneous sources (Vaske et al.,
2010). In this paper, analysis methods were compared according
to types of input, scoring algorithms, results, and user accessibil-
ity. Each of these aspects presents its own particular challenges.
The validation of pathway analysis results is an important
challenge researchers face when trying to develop such meth-
ods. While biologists are needed to verify the pathway analysis
results, they depend on pathway analysis methods to support
their hypotheses. Most efficient progress will occur with a high
level of communication and collaboration between experiment
biologists, annotators, pathway designers, bioinformaticians, and
computer scientists. As pathway knowledge becomes more com-
plete, the challenge of leveraging this information to extract
biological insight from high throughput data will be redefined.
Until then, advances will be incremental. Gold standard experi-
ment data sets, designed to affect specific pathways in predefined
ways, will be necessary to be able to assess the efficiency of new
methods.
Another challenge we mentioned in this survey is that the
same biological pathways are represented differently from one
pathway database to another. In particular, we pointed out the
complications arising from inconsistent conversions for repre-
senting interactions among the different pathway databases, and
the current efforts to address the problem through the creation of
unified formats. However, none of the tools is compatible with
all database formats, requiring either modification of pathway
input or alteration of the underlying algorithm in order to accom-
modate the differences. As an example, a study by Vaske and
others (Vaske et al., 2010) attempts to compare SPIA (Tarca et al.,
2013) with their tool PARADIGM, by re-implementing SPIA in
C, and forcing its compatibility with NCI-PID pathways. Grave
implementation errors are present in the C version of SPIA, inval-
idating the comparison. A solution to overcome this challenge
could be the development of a unified globally accepted pathway
format. Another possible solution is to build conversion software
tools that can translate between pathway formats. Some attempts
exist to use BIO-PAX as the lingua franca for this domain.
Biological networks are divided in various categories con-
taining complementary information. Signaling and signal trans-
duction are captured by signaling pathways, while biochemical
interactions are presented in metabolic pathways. In addition,
the protein interaction knowledge bases contain different types
of interaction information, complementary to the others. The
majority of pathway databases are manually curated and change
slowly, but they are evolving toward greater content and accu-
racy, with new prototype formats being proposed. There is no
analysis method that takes advantage of the information stored
in all of these different sources. Few of the methods surveyed
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Table 2 | Comparison of topology-based pathway analysis methods using criteria related to the mathematical model and implementation.
Method name Graph model Scoring method Availability License Language Available from
ScorePAGE Single-type, undirected Hierarchical, similarity Standalone N/A R on demand
MetaCore* Single-type, directed Hierarchical, graph measures Web-based,
Standalone
Thomson
Reuters
Java Reuters, 2013
Pathway-Express Single-type, directed Hierarchical, graph measures Web-based,
Standalone
free** Java,R Dra˘ghici et al., 2013
TAPPA Single-type, undirected Hierarchical, NNV Standalone N/A Java N/A
PathOlogist Multi-type, directed Hierarchical, probability Standalone CC-BY MATLAB Greenblum et al., 2013
Pathway-Guide* Single-type, directed Hierarchical, graph measures Standalone Advaita
Corporation,
2013
Java Advaita Corporation,
2013
SPIA Single-type, directed Hierarchical, graph measures Standalone GPL (>=2) R Tarca et al., 2013
NetGSA Single-type, directed Mutivariate, hypothesis test Standalone GPL-2 R Shojaie, 2013
PWEA Single-type, undirected Hierarchical, similarity Standalone free** C++ Hung, 2013
TopoGSA Single-type, undirected Hierarchical, graph measures Web-based free** PHP, R Glaab et al., 2013
PARADIGM Multi-type, directed Hierarchical, probability Web-based,
Standalone
free**
(standalone)
UCSC-CGB
(web-based)
C Vaske and Benz, 2013b,
Vaske and Benz, 2013a
TopologyGSA Single-type, moral
undirected
Mutivariate, hypothesis test Standalone AGPL-3 R Massa and Sales, 2013
DEGraph Single-type, undirected Mutivariate, hypothesis test Standalone GPL-3 R Jacob et al., 2013
MetPA Single-type, directed Hierarchical, graph measures Web-based free** PHP, R Xia, 2013
BPA Single-type, DAG Mutivariate, Bayesian
network
Standalone free** MATLAB Isci, 2013
GANPA Single-type, undirected Hierarchical, graph measures Standalone GPL-2 R Fang et al., 2013
BAPA-IGGFD Single-type, DAG Mutivariate, Bayesian
network
Standalone N/A R N/A
CePa Single-type, directed Hierarchical, graph measures Web-based,
Standalone
GPL (>= 2) R Gu, 2013b,
Gu, 2013a
THINK-Back-DS Single-type, directed Hierarchical, graph measures Web-based,
Standalone
free** Java Farfán et al., 2013b,
Farfán et al., 2013a
TBScore Single-type, directed Hierarchical, normalized
node value (NNV)
N/A N/A N/A N/A
ACST Single-type, directed Hierarchical, NNV Standalone CC-BY R Mieczkowski et al., 2013
EnrichNet Single-type, undirected Hierarchical, graph measures Web-based free** PHP Glaab, 2013
*commercial methods; **free for academic and non-commercial use; UCSC-CGB – the University of California Santa Cruz Cancer Genome Browser;
N/A No publicly available implementation, Graph model indicates whether the graph which is remodeled to be suitable for the scoring method is single-type or
multi-type and whether it is directed or undirected. DAG stands for directed acyclic graph. The moral graph is described in Section 3.1. Scoring method encloses the
mathematical model used in the analysis to score nodes and graphs. A detailed description is presented in Section 3.2. Implementation indicates the existence of a
standalone or web-based implementation of the method. License represents the license under which the software is available. GPL - GNU General Public License,
AGPL - GNU Affero General Public License, CC-BY - Creative Commons license. Language represents the programming language used for the implementation.
Available from points to the paper or url associated with the given tool.
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here use either signaling or metabolic pathways in addition to
PPI networks. Promising developments include the integration
of multiple component types and interaction types, each with
specific properties. Although the information is less reliable, non-
curated high-throughput protein interaction data is also proving
useful, as protein interaction data can be used to support or filter
results.
High-throughput technologies, developed for biological
experiments, are improving in accuracy. However, they are still
prone to error and the resulting data includes a significant
amount of noise. In addition, these technologies produce vari-
ous types of data among which are genome variations, mRNA
level, metabolite concentration, or protein abundance. Each of
these data types provides meaningful yet incomplete information
regarding specific biological phenomena. The next challenge is to
be able to integrate such diverse types of data.
Another challenge is the oversimplification that characterizes
many of the models provided by pathway databases. In principle,
each type of tissue might have different mechanisms so generic,
organism-level pathways present a somewhat simplistic descrip-
tion of the phenomena. Furthermore, signaling and metabolic
processes can also be different from one condition to another,
or even from one patient to another. Understanding the specific
pathways that are impacted in a given phenotype or sub-group of
patients should be another goal for the next generation of pathway
analysis tools.
Interpreting biological experimental data is also challenging
due to inaccurate assumptions. For instance, most current path-
way models show cascades of signals or biochemical processes
next to one another, in time-agnostic diagrams. In reality, these
phenomena happen over time, and often at different time scales.
Furthermore, many data sets offer only a snapshot in time, at a
particular moment. Almost by definition, such a frozen snapshot
cannot properly capture and show the effect of successive events
that take place over time.
The graphical scoring methods presented in this paper are
representative of the techniques available for future methods.
We expect to see greater use of different types of data, in addi-
tion to greater use of data mining and machine learning which
will lead to more sophisticated topology-based pathway analysis
methods.
It is important to (re-)state that the goal of this paper was to
survey the main topology-based techniques and methods avail-
able to identify the most significant pathways in a comparison
between phenotypes. In other words, the goal was to identify,
categorize and review these methods without attempting to assess
their performance. A critical assessment and ranking will be the
subject of a later publication. A natural tendency would be to
try to use the various criteria used here to compare various
methods and thus establish even a partial ordering. For instance,
if method X uses only one type of input (e.g., pathways from
KEGG) while method Y uses two types of input (e.g., pathways
from KEGG as well as PPI data), one might be tempted to con-
clude that method Y is somewhat more powerful than method X.
Similarly, some methods use a subset of DE genes while others
use the entire set of measured values. Again, it may be tempting
to informally conclude that the later methods are more pow-
erful since, they take more data into consideration or because
they eliminate the need for a selection of DE genes. It is our
opinion that such inferences and partial orderings are not advis-
able and should not be attempted based on the information
presented in this paper. A proper assessment of these methods
should be focused on their ability to identify the pathways that
are truly impacted in the given phenotypes, and not based on
superficial characteristics or number of features of one type or
another.
ACKNOWLEDGMENTS
This work has been partially supported by the following grants:
NIH RO1 DK089167, NIH STTR R42GM087013, and NSF DBI-
0965741 (to Sorin Dra˘ghici). Any opinions, findings, and conclu-
sions or recommendations expressed in this material are those of
the authors and do not necessarily reflect the views of any of the
funding agencies.
REFERENCES
Abdi, A., and Emamian, E. S. (2010).
Fault diagnosis engineering in
molecular signaling networks:
an overview and applications
in target discovery. Chem.
Biodivers. 7, 1111–1123. doi:
10.1002/cbdv.200900315
Advaita Corporation. (2013) Pathway-
Guide Software. Available online
at: http://www.advaitabio.com/
products.html (Accessed on May
15, 2013)
Aittokallio, T., and Schwikowski, B.
(2006). Graph–based methods
for analysing networks in cell biol-
ogy. Brief. Bioinf. 7, 243–255. doi:
10.1093/bib/bbl022
Arrell, D. K., and Terzic, A. (2010).
Network systems biology for drug
discovery. Clin. Pharmacol. Ther. 88,
120–125. doi: 10.1038/clpt.2010.91
Bader, G. D., Donaldson, I., Wolting, C,
Ouellette, F. B. F., Pawson, T., and
Hogue, C. W. V. (2001). BIND–
the biomolecular interaction net-
work database. Nucleic Acids
Res. 29, 242–245. doi: 10.1093/nar/
29.1.242
Barabási, A. L., Gulbahce, N., and
Loscalzo, J. (2011). Network
medicine: a network–based
approach to human disease.
Nat. Rev. Genet. 12, 56–68. doi:
10.1038/nrg2918
Beltrame, L., Calura, E., Popovici, R. R.,
Rizzetto, L., Guedez, D. R., Donato,
M., et al. (2011). The biologi-
cal connection markup language: a
SBGN-compliant format for visu-
alization, filtering and analysis of
biological pathways. Bioinformatics
27, 2127–2133. doi: 10.1093/bioin-
formatics/btr339
Ben-Shaul, Y., Bergman, H., and Soreq,
H. (2005). Identifying subtle
interrelated changes in functional
gene categories using continu-
ous measures of gene expression.
Bioinformatics 21, 1129–1137. doi:
10.1093/bioinformatics/bti149
BioCarta. (2000). BioCarta - Charting
Pathways of Life. Technical report,
BioCarta. Available online at: http://
www.biocarta.com
BioPAX. (2002). The Biological Pathway
Exchange (BioPAX). Available
online at: http://www.biopax.org
Chowbina, S. R., Wu, X., Zhang, F.,
Li, P. M., Pandey, R., Kasamsetty,
H. N., et al. (2009). HPD:
an online integrated human
pathway database enabling sys-
tems biology studies. BMC
Bioinformatics 10(Suppl. 11):S5.
doi: 10.1186/1471-2105-10-S11-S5
Chuang, H. Y., Hofree, M., and Ideker,
T. (2010). A decade of systems
biology. Ann. Rev. Cell Dev. Biol.
26, 721–744. doi: 10.1146/annurev-
cellbio-100109-104122
Chung, F. R. K. (1997). Spectral Graph
Theory. Providence, RI: American
Mathematical Society.
Dezso˝, Z., Nikolsky, Y., Nikolskaya, Y,
Miller, J., Cherba, D.,Webb, C., et al.
(2009). Identifying disease-specific
genes based on their topological sig-
nificance in protein networks. BMC
Syst. Biol. 3:36. doi: 10.1186/1752-
0509-3-36
Dra˘ghici, S., Khatri, P., and Voichit¸a,
C. (2013) Pathway-Express Software.
Available online at: http://vortex.cs.
wayne.edu/projects.htm.
Draˇghici, S., Khatri, P., Tarca, A. L.,
Amin, K., Done, A., Voichit¸a, C.,
et al. (2007). A systems biology
Frontiers in Physiology | Computational Physiology and Medicine October 2013 | Volume 4 | Article 278 | 20
Mitrea et al. Topology-based pathway analysis methods
approach for pathway level analy-
sis. Genome Res. 17, 1537–1545. doi:
10.1101/gr.6202607
Efron, B. (1979). Bootstrap meth-
ods: another look at the jack-
knife. Ann. Stat. 7, 1–26. doi:
10.1214/aos/1176344552
Efron, B., and Tibshirani, R. (2007).
On testing the significance of sets of
genes. Ann. Appl. Stat. 1, 107–129.
doi: 10.1214/07-AOAS101
Efroni, S., Schaefer, C. F., and Buetow,
K. H. (2007). Identification of
key processes underlying can-
cer phenotypes using biologic
pathway analysis. PLoS ONE
2:e425. doi: 10.1371/journal.pone.
0000425
Emmert-Streib, F., and Glazko, G. V.
(2011). Pathway analysis of expres-
sion data: deciphering functional
building blocks of complex diseases.
PLoS Comput. Biol. 7:e1002053. doi:
10.1371/journal.pcbi.1002053
Fang, Z., Tian, W., and Ji, H. (2011).
A network-based gene-weighting
approach for pathway analy-
sis. Cell Res. 22, 565–580. doi:
10.1038/cr.2011.149
Fang, Z., Tian, W., and Ji, H. (2013).
GANPA Software . Available online
at: http://cran.r-project.org/web/
packages/GANPA/index.html (Acce
ssed on May, 2013)
Farfán, F., Ma, J, Sartor, M. A.,
Michailidis, G., and Jagadish,
H. V. (2012). THINK Back:
knowledge-based interpretation
of high throughput data. BMC
Bioinformatics 13(Suppl 2):S4. doi:
10.1186/1471-2105-13-S2-S4
Farfán, F., Ma, J., Sartor, M. A.,
Michailidis, G., and Jagadish, H. V.
(2013a). THINK-Back-DS Software
Standalone. Available online
at: http://eecs.umich.edu/db/
think/files/densityanalysis1.0.zip, a
(Accessed on May, 2013)
Farfán, F., Ma, J., Sartor, M. A.,
Michailidis, G., and Jagadish, H. V.
(2013b). THINK-Back-DS Software
Web-Based. Avaialble onlne
at: http://eecs.umich.edu/db/think/
software.html, (Accessed on May,
2013)
Gao, S., and Wang, X. (2007). TAPPA:
topological analysis of pathway phe-
notype association. Bioinformatics
23, 3100–3102. doi: 10.1093/bioin-
formatics/btm460
Glaab, E. (2013). EnrichNet Software.
Available online at: http://www.
enrichnet.org, (Accessed onMay 15,
2013).
Glaab, E., Baudot, A., Krasnogor, N.,
Schneider, R., and Valencia, A.
(2012). EnrichNet: network-based
gene set enrichment analysis.
Bioinformatics 28, i451–i457. doi:
10.1093/bioinformatics/bts389
Glaab, E., Baudot, A., Krasnogor, N.,
Schneider, R., and Valencia, A.
(2010). TopoGSA: network topolog-
ical gene set analysis. Bioinformatics
26, 1271–1272. doi: 10.1093/bioin-
formatics/btq131
Glaab, E., Baudot, A., Krasnogor,
N., Schneider, R., and Valencia,
A. (2013). TopoGSA Software.
Available online at: http://www.
infobiotics.net/topogsa (Accessed
on May 15, 2013).
Greenblum, S. I ., Efroni, S., Schaefer,
C. F., and Buetow, K. H. (2013).
Pathologist Software. Available
online at: ftp://ftp1.nci.nih.gov/
pub/pathologist/ (Accessed on May
15, 2013).
Gu, Z. (2013a). CePa Software
Standalone. Available online
at: http://cran.r-project.org/web/
packages/CePa/index.html (Acce
ssed on May 15, 2013).
Gu, Z. (2013b). CePa Software
Web-Based. Available online
at: http://mcube.nju.edu.cn/
cgi-bin/cepa/main.pl (Accessed on
May 15, 2013).
Gu, Z., Liu, J., Cao, K., Zhang, J.,
and Wang, J. (2012). Centrality-
based pathway enrichment: a sys-
tematic approach for finding signif-
icant pathways dominated by key
genes. BMC Syst. Biol. 6:56. doi:
10.1186/1752-0509-6-56
Hermjakob, H., Montecchi-Palazzi, L.,
Lewington, C., Mudali, S., Kerrien,
S., Orchard, S., et al. (2004). IntAct:
an open source molecular inter-
action database. Nucleic Acids
Res. 32(Suppl. 1), D452–D455.doi:
10.1093/nar/gkh052
Hung, J.-H. (2013). PWEA Software
Available Online at: http://zlab.bu.
edu/PWEA/ 2013. (Accessed on
May 15, 2013).
Hung, J.-H., Whitfield, T. W., Yang, T.-
H., Hu, Z., Weng, Z., and DeLisi,
C. (2010). Identification of func-
tional modules that correlate with
phenotypic difference: the influence
of network topology. Genome
Biol. 11:R23. doi: 10.1186/gb-2010-
11-2-r23
Ibrahim, M. A., Jassim, S., Cawthorne,
M. A., and Langlands, K.
(2012). A topology-based score
for pathway enrichment. J.
Comput. Biol. 19, 563–573. doi:
10.1089/cmb.2011.0182
Isci, S. (2013). BPA Software Available
online at: http://bumil.boun.edu.tr/
bpa (Accessed on May 15, 2013).
Isci, S., Ozturk, C., Jones, J., and Otu,
H. H. (2011). Pathway analysis
of high-throughput biological data
within a bayesian network frame-
work. Bioinformatics 27, 1667–1674.
doi: 10.1093/bioinformatics/btr269
Jacob, L., Neuvial, P., and Dudoit,
S. (2010). “Gains in power
from structured two-sample
tests of means on graphs,” in
Technical Report 271, Department of
Statistics, Berkeley, CA: University
of California. Available online at:
http://arxiv.org/abs/1009.5173
Jacob, L., Neuvial, P., and
Dudoit, S. (2013). DEGraph
Software. Available online
at: http://www.bioconductor.org/pac
kages/2.12/bioc/html/DEGraph.html
(Accessed on May 15, 2013).
Joshi-Tope, G., Gillespie, M., Vastrik,
I., D’Eustachio, P., Schmidt,
E., de Bono, B., et al. (2005).
REACTOME: a knowledgebase
of biological pathways. Nucleic
Acids Res. 33, D428–D432. doi:
10.1093/nar/gki072
Kelder, T., Conklin, B. R., Evelo, C. T.,
and Pico, A. R. (2010). Finding the
right questions: exploratory path-
way analysis to enhance biological
discovery in large datasets. PLoS
Biol. 8:e1000472. doi: 10.1371/jour-
nal.pbio.1000472
Khatri, P., Sellamuthu, S., Malhotra,
P., Amin, K., Done, A., and
Draˇghici, S. (2005). Recent addi-
tions and improvements to the
Onto-Tools. Nucleic Acids Res.
33(Suppl. 2), W762–W765. doi:
10.1093/nar/gki472
Khatri, P., Sirota, M., and Butte, A. J.
(2012). Ten years of pathway anal-
ysis: current approaches and out-
standing challenges. PLoS Comput.
Biol. 8:e1002375. doi: 10.1371/jour-
nal.pcbi.1002375
Khatri, P., Voichit¸a, C., Kattan, K.,
Ansari, N., Khatri, A., Georgescu,
C., et al. (2007). Onto-Tools:
new additions and improvements
in 2006. Nucleic Acids Res. 37,
W206–W211. doi: 10.1093/nar/
gkm327
Kullback, S., and Leibler, R. A. (1951).
On information and sufficiency.
Ann. Math. Stat. 22, 79–86. doi:
10.1214/aoms/1177729694
Lauritzen, S. L. (1996). Graphical
Models, Vol. 17. Oxford: Oxford
University Press.
Mantel, N. (1966). Evaluation of sur-
vival data and two new rank order
statistics arising in its considera-
tion. Cancer Chemother. Rep. 50,
163–170.
Massa, M. S., Chiogna, M., and
Romualdi, C. (2010). Gene set
analysis exploiting the topology of a
pathway. BMC Syst. Biol. 4:121. doi:
10.1186/1752-0509-4-121
Massa S., and Sales, G. (2013).
TopologyGSA Software. Available
online at: http://cran.r-project.org/
web/packages/topologyGSA/index.
html (Accessed on May 15, 2013).
McLean, R. A., Sanders, W. L., and
Stroup, W. W. (1991). A uni-
fied approach to mixed linear mod-
els. Am. Stat. 45, 54–64. doi:
10.1080/00031305.1991.10475767
Mewes, H.-W., Heumann, K., Kaps, A.,
Mayer, K., Pfeiffer, F., Stocker, S.,
et al. (1999). MIPS: a database
for genomes and protein sequences.
Nucleic Acids Res. 27, 44–48.doi:
10.1093/nar/27.1.44
Mi, H., Lazareva-Ulitsky, B., Loo,
R., Kejariwal, A., Vandergriff, J.,
Rabkin, S., et al. (2005). The
PANTHER database of protein
families, subfamilies, functions
and pathways. Nucleic Acids Res.
33(Suppl. 1), D284–D288. doi:
10.1093/nar/gki078
Mieczkowski, J., Swiatek-Machado,
K., and Kaminska, B. (2012).
Identification of pathway
deregulation–gene expression
based analysis of consistent signal
transduction. PLoS ONE 7:e41541.
doi: 10.1371/journal.pone.0041541
Mieczkowski, J., Swiatek-Machado, K.,
and Kaminska, B. (2013). ACST
Software. Available online at: http://
www.plosone.org/article/info:doi/
10.1371/journal.pone.0041541#s4
(Accessed on May 15, 2013).
Misman, M. F., Deris, S., Hashim, S.
Z. M., Jumali, R., and Mohamad,
M. S. (2009). “Pathway-based
microarray analysis for defining
statistical significant phenotype-
related pathways: a review of
common approaches,” in ICIME’09.
International Conference on
Information Management and
Engineering, 2009 (IEEE), (Kuala
Lumpur), 496–500. doi: 10.1109/
ICIME.2009.103
Nam, D., and Kim, S.-Y. (2008). Gene-
set approach for expression pattern
analysis. Brief. Bioinf. 9, 189–197.
doi: 10.1093/bib/bbn001
Neapolitan, R. E. (2004). Learning
Bayesian Networks. Prentice Hall.
Ogata, H., Goto, S., Sato, K., Fujibuchi,
W., Bono, H., and Kanehisa, M.
(1999). KEGG: kyoto encyclo-
pedia of genes and genomes.
Nucleic Acids Res. 27, 29–34. doi:
10.1093/nar/27.1.29
Pan, K.-H., Lih, C.-J., and Cohen, S. N.
(2005). Effects of threshold choice
on biological conclusions reached
during analysis of gene expression
by dna microarrays. Proc. Natl.
Acad. Sci. U.S.A. 102, 8961–8965.
doi: 10.1073/pnas.0502674102
www.frontiersin.org October 2013 | Volume 4 | Article 278 | 21
Mitrea et al. Topology-based pathway analysis methods
Peri, S., Navarro, J. D., Kristiansen,
T. Z., Amanchy, R., Surendranath,
V., Muthusamy, B., et al. (2004).
Human protein reference database
as a discovery resource for pro-
teomics. Nucleic Acids Res.
32(Suppl. 1), D497–D501. doi:
10.1093/nar/gkh070
Pico, A. R., Kelder, T., van Iersel, M.
P., Hanspers, K., Conklin, B. R., and
Evelo, C. (2008). WikiPathways:
pathway editing for the people.
PLoS Biol. 6:e184. doi: 10.1371/jour-
nal.pbio.0060184
Rahnenführer, J., Domingues, F. S.,
Maydt, J., and Lengauer, J. (2004).
Calculating the statistical signifi-
cance of changes in pathway activ-
ity from gene expression data. Stat.
Appl. Genet. Mol. Biol. 3. doi:
10.2202/1544-6115.1055
Reuters, T. (2013). MetaCore
Software. Available online at:
http://www.genego.com/metacore.
php. (Accessed on May 15 , 2013).
Sartor, M. A., Leikauf, G. D., and
Medvedovic, M. (2009). LRpath:
a logistic regression approach for
identifying enriched biological
groups in gene expression data.
Bioinformatics 25, 211–217. doi:
10.1093/bioinformatics/btn592
Schaefer, C. F., Anthony, K., Krupa, S.,
Buchoff, J., Day, M., Hannay, T.,
et al. (2009). PID: the pathway
interaction database. Nucleic Acids
Res. 37(Suppl. 1), D674–D679. doi:
10.1093/nar/gkn653
Shojaie, A. (2013). NetGSA
Software. Available online at:
http://www.biostat.washington.edu/
∼ashojaie/software/netGSA_1.0.ta
r.gz. (Accessed on May 15, 2013).
Shojaie, A., and Michailidis, G. (2009).
Analysis of gene sets based on the
underlying regulatory network. J.
Comput. Biol. 16, 407–426. doi:
10.1089/cmb.2008.0081
Shojaie, A., and Michailidis, G. (2010).
Network enrichment analysis in
complex experiments. Stat. Appl.
Genet. Mol. Biol. 9. doi: 10.2202/
1544-6115.1483
Snel, R., Lehmann, G., Bork, P., and
Huynen, M. A. (2000). STRING:
a web-server to retrieve and dis-
play the repeatedly occurring
neighbourhood of a gene. Nucleic
Acids Res. 28, 3442–3444. doi:
10.1093/nar/28.18.3442
Spirtes, P. (1995). “Directed cyclic
graphical representations of feed-
back models,” in Proceedings
of the Eleventh Conference on
Uncertainty in Artificial Intelligence
(Morgan Kaufmann Publishers
Inc.), (Montreal, QC), 491–498.
Stark, C., Breitkreutz, B. J., Reguly,
T., Boucher, L., Breitkreutz, A.,
and Tyers, M. (2006). BioGRID:
a general repository for interac-
tion datasets. Nucleic Acids Res.
34(Suppl. 1), D535–D539. doi:
10.1093/nar/gkj109
Steuer, R. (2007). Computational
approaches to the topol-
ogy, stability and dynamics
of metabolic networks.
Phytochemistry 68, 2139–2151. doi:
10.1016/j.phytochem.2007.04.041
Subramanian, A., Tamayo, B., Mootha,
V. K., Mukherjee, S., Ebert, B.
L., Gillette, M. A., et al. (2005).
Gene set enrichment analysis: a
knowledge-based approach for
interpreting genome-wide expres-
sion profiles. Proc. Natl. Acad.
Sci. U.S.A. 102, 15545–15550. doi:
10.1073/pnas.0506580102
Tarca, A. L., Draˇghici, S., Bhatti,
G., and Romero, R. (2012).
Down-weighting overlapping
genes improves gene set analysis.
BMC Bioinformatics 13:136. doi:
10.1186/1471-2105-13-136
Tarca, A. L., Draˇghici, S., Khatri,
P., Hassan. S. S., Mittal, P., sun
Kim, J., et al. (2009). A novel
signaling pathway impact analysis
(SPIA). Bioinformatics 25, 75–82.
doi: 10.1093/bioinformatics/btn577
Tarca, A. L., Khatri, P., and
Dra˘ghici, S. (2013). SPIA
Software. Available online at:
http://bioconductor.org/packages/rel
ease/bioc/html/SPIA.html, (Accessed
on May 15, 2013).
Varadan, V., Mittal, P., Vaske, C. J., and
Benz, S. C. (2012). The integra-
tion of biological pathway knowl-
edge in cancer genomics: a review of
existing computational approaches.
Signal Process. Mag. IEEE 29, 35–50.
doi: 10.1109/MSP.2011.943037
Vaske, C. J., and Benz, S. C. (2013a).
PARADIGM Software Standalone.
Available online at: http://sbenz.
github.com/Paradigm, (Accessed
on May 15, 2013).
Vaske, C. J., and Benz, S. C. (2013b).
PARADIGM Software Web-
Based. Available online at: https://
genome-cancer.ucsc.edu/proj/site/
hgHeatmap/, (Accessed on May 15,
2013).
Vaske, C. J., Benz, S. C., Sanborn,
J. Z., Earl, D., Szeto, C., Zhu,
J., et al. (2010). Inference of
patient-specific pathway activities
from multi-dimensional cancer
genomics data using PARADIGM.
Bioinformatics 26, i237–i245.
doi: 10.1093/bioinformatics/
btq182
Voichit¸a, C, Donato, M., and Draˇghici,
S. (2012). “Incorporating gene
significance in the impact analysis
of signaling pathways,” in Machine
Learning and Applications (ICMLA),
2012 11th International Conference
on, IEEE. Vol. 1, (Boca Raton, FL),
126–131.
Von Mering, C, Huynen, M., Jaeggi,
D., Schmidt, S, Bork, P., and Snel,
S. (2003). STRING: a database
of predicted functional associa-
tions between proteins. Nucleic
Acids Res. 31, 258–261. doi:
10.1093/nar/gkg034
Watts, D. J., and Strogatz, S. H.
(1998). Collective dynamics of
‘small-world’ networks. Nature 393,
440–442. doi: 10.1038/30918
Xenarios, I., Rice, D. W., Salwinski,
L., Baron, M. K., Marcotte, E. M.,
and Eisenberg, D. (2000). DIP:
the database of interacting proteins.
Nucleic Acids Res. 28, 289–291. doi:
10.1093/nar/28.1.289
Xia, J. (2013). MetPA Software .
Available online at: http://metpa.
metabolomics.ca. (Accessed onMay
15, 2013).
Xia, J., and Wishart, D. S.
(2010). MetPA: a web-based
metabolomics tool for path-
way analysis and visualization.
Bioinformatics 26, 2342–2344. doi:
10.1093/bioinformatics/btq418
Yin, E., Gupta, M., Weninger, T.,
and Han, J. (2010). “A unified
framework for link recommen-
dation using random walks,” in
Advances in Social Networks Analysis
and Mining (ASONAM), 2010
International Conference on, IEEE,
(Odense), 152–159.
Zhao, Y., Chen, M. H., Pei, H., Rowe,
D., Shin, D. G., Xie, G., et al.
(2012). A Bayesian approach to
pathway analysis by integrating
gene–gene functional directions
and microarray data. Stat. Biosci. 4,
105–131. doi: 10.1007/s12561-011-
9046-1
Conflict of Interest Statement: Sorin
Dra˘ghici is the founder and CEO of
Advaita Corporation, a Wayne State
University spin-off that commercializes
Pathway-Guide, one of the pathway
analysis tools mentioned in this arti-
cle. The other authors declare that
the research was conducted in the
absence of any commercial financial
relationships that could construed as a
potential conflict interest.
Received: 31 May 2013; accepted: 15
September 2013; published online: 10
October 2013.
Citation: Mitrea C, Taghavi Z,
Bokanizad B, Hanoudi S, Tagett R,
Donato M, Voichi¸ta C and Dra˘ghici S
(2013) Methods and approaches in the
topology-based analysis of biological
pathways. Front. Physiol. 4:278. doi:
10.3389/fphys.2013.00278
This article was submitted to
Computational Physiology and
Medicine, a section of the journal
Frontiers in Physiology.
Copyright © 2013 Mitrea, Taghavi,
Bokanizad, Hanoudi, Tagett, Donato,
Voichi¸ta and Dra˘ghici. This is an open-
access article distributed under the terms
of the Creative Commons Attribution
License (CC BY). The use, distribution or
reproduction in other forums is permit-
ted, provided the original author(s) or
licensor are credited and that the origi-
nal publication in this journal is cited, in
accordance with accepted academic prac-
tice. No use, distribution or reproduction
is permitted which does not comply with
these terms.
Frontiers in Physiology | Computational Physiology and Medicine October 2013 | Volume 4 | Article 278 | 22
